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Abstract 
 Obesity is the largest risk factor for the development of obstructive sleep apnea 
syndrome (OSAS), which is a common sleep-related breathing disorder that is associated 
with cognitive dysfunction. A growing body of literature suggests that obesity is related 
to negative neuropsychological outcomes independent of other health problems known to 
impact cognitive functioning (e.g., type II diabetes, cardiovascular disease).  The purpose 
of this study was to investigate the impact of obesity on the cognitive functioning of 
individuals with OSAS.  Specifically, this study aimed to examine whether or not 
differences existed between obese and non-obese persons with OSAS on a battery of 
cognitive tests that assessed memory, attention, and executive functions both at baseline 
and over six months of continuous positive airway pressure (CPAP) treatment. This study 
utilized data from Project Breathe, which was a study conducted at National Jewish 
Health. It was hypothesized that obese participants with OSAS would demonstrate poorer 
baseline performance on tests of memory, attention, and executive functioning, and they 
would show lesser improvement in these cognitive domains over six months of CPAP 
treatment compared to non-obese participants. Analysis of covariance (ANCOVA) and 
repeated measures analysis of covariance (RM-ANCOVA) tests were used to analyze the 
data. Results indicate that obese and non-obese participants did not demonstrate 
differences in neurocognitive functioning at baseline or following six months of CPAP 
treatment after adjusting for age and hypertension. Several limitations, including how 
 iii 
obesity was measured, analyses used, and low statistical power may have contributed to 
the lack of significant findings in the predicted direction. Future research should focus on 
the following: larger sample sizes; using measures of obesity other than or in addition to 
body mass index (BMI); and examining the moderating impact of sex on neurocognitive 
functioning in this population.  
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Chapter I: Introduction 
Obesity and Obstructive Sleep Apnea Syndrome 
 Obesity is highly prevalent in the United States, and it is a growing health 
problem in other nations around the world (World Health Organization [WHO], 1998). 
Obesity results from the accumulation of excess body fat and is associated with myriad 
health problems and increased mortality (Olshansky et al., 2005). Obesity is one of the 
foremost risk factors for obstructive sleep apnea syndrome (OSAS), which is a common 
sleep-related breathing disorder characterized by repetitive episodes of upper airway 
collapse during sleep that cause breathing cessation and result in fragmented sleep and 
intermittent hypoxemia (American Academy of Sleep Medicine, 1999).   
Obstructive Sleep Apnea Syndrome and Neuropsychological Impairment  
 OSAS is associated with several neuropsychological deficits, which are well 
documented in the literature. Those most frequently reported by OSAS patients and 
strongly acknowledged in the literature include problems with attention and vigilance 
(Bédard et al., 1991; Bédard et al., 1993; Findley et al., 1986; Ferini-Strambi et al., 2003; 
Greenberg et al., 1987; Munoz et al., 2000; Naegele et al., 1995; Redline et al., 1997). 
Some research suggests that impairments in attention/vigilance are related to apnea 
severity, specifically, the level of sleep fragmentation, as opposed to nocturnal 
hypoxemia (Bédard et al., 1991).  
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The literature also indicates that OSAS is associated with impairments in 
executive functions (Bédard et al., 1991; Greenberg et al., 1987; Kales et al., 1985; Lee et 
al., 1999; Naegele et al., 1995; Redline et al., 1997; Salorio et al., 2002). However, lack 
of consistency across studies in measures used to test executive functions obscure the 
specific aspects of executing functioning (e.g., working memory, cognitive flexibility, 
planning) that are impacted by OSAS. Investigators have argued that deficiencies in 
executive functions are related to nocturnal hypoxemia, as opposed to sleep 
fragmentation (Bédard et al., 1993; Ferini-Strambi et al., 2003; Valencia-Flores et al., 
1996; Montplaisir et al., 1992).    
The literature points to a relationship between OSAS and memory deficits 
(Bédard et al., 1991; Berry et al., 1986; Findley et al., 1986; Naegele et al., 1995; Kales et 
al., 1985); however, like executive functions, investigators have not reached consensus 
regarding the specific components of memory that are impacted due to divergent memory 
assessment methods across studies. The majority of studies have investigated the 
relationship between OSAS and impaired long-term visual and verbal memory (Bédard et 
al., 1991; Berry et al., 1986; Findley et al., 1986; Naegele et al., 1995; Kales et al., 1985). 
However, Kales et al. (1985) also found a relationship between OSAS and decrements in 
short-term visual and verbal memory. Investigators have attributed these memory deficits 
to both nocturnal hypoxemia (Findley et al., 1986) and sleep fragmentation (Kales et al., 
1985; Bédard et al., 1991).   
 Several researchers have highlighted a clear relationship between OSAS and 
impaired fine motor coordination mediated by the brain (Bédard et al., 1991; Bédard et 
al., 1993; Greenberg et al., 1987). These investigators have observed associations 
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between fine motor coordination and nocturnal hypoxemia. Further, the literature 
suggests that impaired fine motor coordination due to OSAS may be irreversible, and 
thus, suggests an association between OSAS and permanent anoxic brain damage (Aloia 
et al., 2004).  
Treatment 
 Oral appliances and surgical procedures are used to treat OSAS; however, the 
majority of patients do not receive adequate clinical benefit from these approaches. 
Considering the estimation that 70 % of persons with OSAS meet criteria for obesity 
(Malhotra & White, 2002), some investigators have analyzed the impact of weight loss as 
a treatment for OSAS. Veasey et al. (2006) found that a sufficient amount of weight loss 
through dietary modification can result in significant improvement in OSAS 
symptomatology among overweight and obese individuals. However, these investigators 
acknowledged that improvements in weight loss programs are warranted. Surprisingly, no 
studies in the extant literature have examined the impact of weight loss on the 
neuropsychological sequelae associated with OSAS.   
Continuous-positive airway pressure (CPAP) is considered the most effective and 
preferred treatment for OSAS (Gay et al., 2006). The CPAP device contains a mask with 
a harness that fits over the head to hold the mask in place, as well as a flexible tube, and 
pump that provides continuous positive air pressure. The positive air pressure to the 
upper portion of the airway prevents it from collapsing during sleep, thus reducing or 
completely eliminating nocturnal respiratory disturbances. The decrease or absence of 
upper airway collapse results in minimized sleep fragmentation and nocturnal hypoxemia 
(American Thoracic Society, 1994). Unfortunately, despite the efficacy of CPAP 
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treatment, it is estimated that 25 - 50 % of individuals prescribed CPAP do not tolerate it 
(Zozula & Rosen, 2001). 
Of the studies reviewed in Chapter II, there appears to be consensus among 
investigators regarding the impact of CPAP treatment on two cognitive constructs: 
attention/vigilance and motor coordination. The majority of studies suggest that 
attention/vigilance improves following CPAP treatment. Improvements in 
attention/vigilance have been observed in as little as 15 days of CPAP treatment (Ferini-
Strambi et al., 2003). However, the literature indicates that fine motor coordination does 
not improve following CPAP treatment (Aloia et al., 2004; Bédard et al., 1993; Beebe et 
al., 2003). Investigators hypothesize that anoxic brain damage associated with repeated 
nocturnal hypoxic events might cause irreversible deficits in this domain of cognitive 
functioning (Aloia et al., 2004).    
It is not clear if CPAP treatment improves memory deficits associated with 
OSAS. Borak et al. (1996) and Bédard et al. (1993) observed that CPAP treatment 
improved memory deficits after three and six months of CPAP treatment, respectively. 
However, Engleman et al. (1993; 1997) and Naegele et al. (1998) found that memory 
functioning did not improve after four weeks and six months of CPAP treatment, 
respectively.   
Mixed results characterize the literature reviewed regarding the effectiveness of 
CPAP treatment in ameliorating executive functioning deficits in patients with OSAS. 
Some research suggests that executive functioning does not improve following CPAP 
treatment (Bédard et al., 1993; Ferini-Strambi et al., 2003; Valencia-Flores et al., 1996; 
Montplaisir et al., 1992). Investigators argue that executive functions may not respond to 
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treatment due to irreversible anoxic brain damage caused by repeated nocturnal 
hypoxemia. However, this hypothesis is not definitive, as some studies have 
demonstrated that executive functions do improve following CPAP treatment (Borak et 
al., 1996; Engleman et al., 1994; Engleman et al., 1997; Naegele et al., 1998). Further, 
the length of CPAP treatment necessary to improve executive functions is not clear. For 
instance, Bédard et al. (1993) found that six months of CPAP treatment did not improve 
executive functioning; however, Engleman et al. (1994, 1997) found improvements in 
certain aspects of executive functioning in as little as four weeks of CPAP treatment.  
Obesity and Neuropsychological Functioning 
 A growing body of literature suggests that obesity is related to negative 
neurocognitive outcomes independent of other health problems (e.g., type II diabetes, 
OSAS, cardiovascular disease). Several researchers have identified relationships between 
obesity and attention deficits (Altfas, 2002; Elias et al., 2005; Cournot et al., 2006). 
However, some investigators have observed that these relationships are no longer 
significant when covariates, such as education, sex, and age were included in their 
models (Cournot et al., 2006; Elias et al., 2005). Further, Gunstad et al. (2010) observed a 
relationship between increased attentional performance and obesity. Therefore, despite 
some evidence that obesity is associated with attentional deficits, this relationship is not 
conclusive in the literature.  
 A number of investigators have observed relationships between obesity and 
executive dysfunction (Chelune et al., 1986; Gunstad et al., 2007; Gunstad et al., 2010; 
Waldstein & Katzel, 2006). The specific aspects of executive functioning that have been 
analyzed and appear to be affected include cognitive flexibility (Gunstad et al., 2010; 
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Chelune et al., 2007), verbal fluency, and planning (Gunstad et al., 2007). Further, there 
appears to be a relationship between obesity concomitant with high blood pressure and 
impaired response inhibition (Waldstein & Katzel, 2006). Overall, the research that has 
been done thus far concerning obesity and executive dysfunction points to a clear 
relationship.  
 Research suggests that there is also a relationship between obesity and memory 
impairments (Cournot et al., 2006; Elias et al., 2003; Elias et al., 2005; Gunstad et al., 
2006; Gunstad et al., 2010). Elias and colleagues (2003, 2005) observed that obese men 
performed significantly more poorly on tests of verbal and visual memory compared to 
non-obese men even when controlling for age, education, occupation, cigarette smoking, 
and health conditions associated with obesity (e.g., type II diabetes). Notably, the 
relationship between obesity and memory deficits was not apparent in women. 
Additionally, Gunstad and colleagues (2007) found that obese individuals demonstrated 
significantly poorer verbal memory compared to non-obese individuals and later 
observed relationships between obesity and impairments in visual and verbal memory 
(Gunstad et al., 2010). By and large, the literature suggests that that obesity is an 
independent risk factor for memory decrements.    
Along with the research analyzing relationships between obesity and impairments 
in different domains of cognitive functioning, several studies have demonstrated 
associations between obesity and dementia and Alzheimer’s disease (Gustafson et al., 
2003; Kivipelto et al., 2005; Razay et al., 2006), as well as compositional changes in the 
brain, characterized by atrophy and increased white matter lesions in older adults 
(Gustafson et al., 2004; Gustafson, Steen, & Skoog, 2004; Jagust et al., 2005; Ward et al., 
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2005). Though there is evidence to suggest relationships between obesity and different 
aspects of neuropsychological impairment, the directional nature of these relationships 
has not been elucidated. Thus, it is unclear whether obesity is the result or cause of 
neuropsychological impairment. Additionally, it is not clear if the neuropsychological 
deficits associated with obesity improve following weight loss.  
   In addition to lack of clarity surrounding the directional relationship between 
obesity and cognitive dysfunction, the mechanisms underlying this relationship are also 
uncertain. Investigators have posited several potential explanations for this association. 
Dagenais et al. (2005) and Waldstein et al. (2006) suggested obesity causes vascular 
changes that prevent optimal blood flow to the brain, and thus, negatively impact 
cognitive performance. Others have pointed to the impact of obesity on glucose tolerance 
and insulin regulation, which are known to impair cognitive functioning (Convit et al., 
2003; Teunissen et al., 2003). Additionally, some have argued that the increasing adipose 
tissue is associated with changes in certain proteins, such as leptin (Gunstad et al., 2008; 
Harvey, 2007; Wilson, Finch, & Harvey, 2002) and brain-derived neurotrophic factor 
(BDNF; Gunstad et al., 2008; Hariri et al., 2003) that may impact cognitive functioning.  
Statement of Purpose, Hypotheses, and Relevance of the Study 
Purpose of the Study. The extant literature suggests that both OSAS and obesity 
are related to deficits in neuropsychological functioning. There is evidence indicating that 
CPAP improves neurocognitive functioning in OSAS patients; however, the impact of 
obesity in the response to CPAP treatment has not been analyzed. Given that obesity is 
independently associated with impaired neurocognitive functioning, it is possible that the 
presence of obesity in OSAS patients could impact both the severity of impairment, as 
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well as their response to CPAP treatment. Further, no studies have examined differences 
in neuropsychological functioning between obese patients with OSAS and non-obese 
patients with OSAS or differences between these groups following CPAP treatment. 
Therefore, the purpose of this study is to elucidate the impact of obesity on the 
neuropsychological functioning of individuals with OSAS. Specifically, the purpose is to 
identify differences between obese and non-obese OSAS patients both at baseline and 
over six months of CPAP treatment.  
Hypotheses. Based on the literature review presented in Chapter II, the following 
hypotheses were formulated:  
Hypothesis I. Obese participants with OSAS will demonstrate poorer baseline 
attention compared to non-obese individuals with OSAS. Additionally, obese participants 
will show lesser improvement in attention over six months of CPAP treatment compared 
to non-obese participants. Attention will be assessed with the Trail Making Test Part A 
and a Psychomotor Vigilance Task. 
Hypothesis II. Obese participants with OSAS will show poorer baseline executive 
functioning than non-obese individuals with OSAS. Further, they will display lesser 
improvement in executive functioning over six months of CPAP treatment compared to 
non-obese participants. Executive functions will be assessed with the Paced Auditory 
Serial Addition Test and the Trail Making Test Part B, which are measures of working 
memory and cognitive flexibility, respectively.  
Hypothesis III. Obese participants with OSAS will demonstrate poorer baseline 
verbal memory than non-obese individuals with OSAS. In addition, obese participants 
will show lesser improvement in verbal memory over six months of CPAP treatment 
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compared to non-obese participants. Immediate and delayed verbal memory will be 
assessed with the Hopkins Verbal Learning Test.  
Relevance of the Study. This study will fill a gap in the literature pertaining to 
the relationships between obesity, OSAS, and neuropsychological functioning both prior 
to and after CPAP treatment. The importance of clarifying these relationships ultimately 
lies in the treatment recommendations and interventions for obese individuals with 
OSAS. If obese patients with OSAS do not demonstrate the same improvements in 
neuropsychological functioning following CPAP treatment as non-obese patients with 
OSAS, additional interventions aimed at weight loss could be warranted for these 
individuals. Thus, this study has the potential to inform the treatment recommendations 
for obese OSAS patients, and could lead to greater efforts in the development of effective 
weight loss programs for this specific population. Ultimately, this study will enhance the 
existing knowledge regarding the impact of obesity on individuals with OSAS and could 
lead to enhanced treatment interventions, outcomes, and quality of life for obese 
individuals with OSAS.   
Summary 
Chapter I presented an introduction to the definitions of obesity and OSAS. 
Additionally, the neuropsychological deficits associated with obesity and OSAS were 
outlined, as well as the impact of CPAP treatment on neuropsychological functioning in 
individuals with OSAS. The purpose of the study and hypotheses were also outlined. 
Chapter II will present a thorough review of the literature pertaining to 
neuropsychological functioning in persons with OSAS and those who are obese.  
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Chapter II: Review of the Literature 
 Chapter II will present a review of the extant literature pertaining to the 
prevalence of obesity and the related health complications, with a salient focus on 
obstructive sleep apnea syndrome (OSAS).  The prevalence and etiology of OSAS will be 
discussed, as well as common treatment interventions.  Additionally, literature regarding 
the neuropsychological functioning of both persons with OSAS and individuals who are 
obese will be reviewed.  The major sections of the literature review will cover the 
research pertinent to the present study, elucidating its relevance. Further, the literature 
review will highlight the research on which this study’s hypotheses were predicated.  
Obesity 
Obesity is characterized by the accumulation of excess body fat that can impair 
health. Obesity is most often estimated using a formula that combines weight and height. 
Body mass index (BMI) is a calculation of weight in kilograms divided by height in 
meters squared. Though BMI is limited in that it does not distinguish fat mass from lean 
mass, it is the most frequently used formula to determine body fat in epidemiological 
studies (Kopelman, 2000). The WHO (1998) proposed a classification system for BMI 
with the definition of overweight as a BMI greater than or equal to 25 kg/m2, obesity as a 
BMI greater than or equal to 30 kg/m2, and morbid obesity as a BMI greater than or equal 
to 40 kg/m2. The decisive factor for defining obesity was based on the strong correlation 
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between BMI of 30 kg/m2 and increased risk of death (Wadden, Brownell, & Foster, 
2002).  
Prevalence. The prevalence of obesity has increased substantially over the past 
four decades and is currently considered one of the foremost causes of preventable death 
in the United States (Mokdad et al., 2004). More than two thirds of adults in the United 
States are now classified as overweight or obese, which has led to predictions that obesity 
will cause the first decline in life expectancy in the past century (Olshansky et al., 2005). 
Obesity is not only increasing in prevalence throughout the United States, it is a growing 
problem in other industrialized and developing countries, and thus, has been deemed a 
“global epidemic” by the World Health Organization (WHO, 1998).  
The etiology of obesity involves two primary factors: genes and environment. 
Genetic features are thought to account for 25 % - 40 % of the variance in BMI 
(Bouchard, 1990). The exact genes that contribute to obesity have not been determined; 
however, single-gene abnormalities have been found to result in obesity in laboratory 
animals and humans (Kopelman, 2000; Wadden, Brownell, & Foster, 2002).  
Susceptibility genes appear to predispose certain individuals to develop obesity 
(Kopelman, 2000). For instance, the obese (ob) gene (Zhang et al., 1994) produces the 
hormone protein product leptin, which has demonstrated a key role in the regulation of 
food intake and body weight in laboratory mice. Researchers have genetically modified 
mice not to produce leptin, which results in obesity; however, this is reversed with the 
replacement of recombinant leptin (Campfield et al., 1995). Based on this research, it 
would be expected that obese individuals have a leptin deficiency, but this has not been 
observed. Rather, most obese persons have high leptin levels proportionate to their body 
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fat (Considine et al., 1996); thus, some researchers hypothesize that obese individuals 
have an insensitivity to leptin similar to the insulin insensitivity present in individuals 
with type II diabetes (Wadden et al., 2002).   
Though susceptibility genes help explain why certain individuals become obese, 
environmental factors play a key role in the development of obesity and best explain its 
increasing prevalence over the past several decades (Wadden et al., 2002). Persons living 
in modernized countries are at greater risk of becoming obese compared to those living in 
lesser-developed societies. Two studies have demonstrated this phenomenon by 
following persons who migrated from underdeveloped to industrialized nations 
(Bhatnager et al., 1995; Ravussin et al., 1994). In both studies, the body weights of 
persons moving to modernized countries significantly increased compared to their 
relatives who remained in their native environment. This discrepancy is best explained by 
“toxic” environmental factors ubiquitous in developed countries, particularly the United 
States (Battle & Brownell, 1997). These toxic factors include the exposure to, and 
availability of energy-dense foods, coupled with an increasingly sedentary lifestyle.  
 Cultural dynamics also play an important role in the obesity epidemic. Obesity 
rates are associated with race, ethnicity, socioeconomic status (SES), and geographic 
location (Centers for Disease Control [CDC], 2011). Obesity is the most prevalent among 
non-Hispanic black Americans, followed by Hispanic Americans, then non-Hispanic 
white Americans (CDC, 2011). People of low income are disproportionately affected by 
obesity, especially women (Wadden, Brownell, & Foster, 2002). Research indicates that 
differences in SES contribute to discrepancies in the prevalence of obesity between white 
Americans and racial and ethnic minorities (Wadden, Brownell, & Foster, 2002), which 
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is not surprising considering the inextricable link between low SES and minority status. 
Additionally, obesity is more prevalent in the Midwest and the South (CDC, 2011).  
Associated Health Complications. Elevated body fat results in significant 
changes in physiological functioning and risk for certain diseases that are related to the 
distribution of adipose tissue. For example, generalized obesity alters total blood volume 
and cardiac functioning, while increased adipose tissue around the rib cage changes 
respiratory functioning. Further, abdominal obesity plays a role in the development of 
type II diabetes and hypertension (Kopelman, 2000). Adams and colleagues (2006) found 
that the risk of mortality at midlife (i.e., 50 years) increases by 20 to 40 percent among 
overweight individuals and by at least two to three times among obese individuals. The 
risk of death associated with obesity is primarily a result of associated health 
complications, including type II diabetes, hypertension, cardiovascular disease, certain 
types of cancer, and sleep-disordered breathing (Pi-Sunyer, 1993).  
Diabetes. Insulin sensitivity can be a consequence of obesity, independent of 
genetics. Katzel, Bugsby-Whitehead, and Goldberg (1993) demonstrated this in a study 
where 23 identical twins were discordant in terms of obesity. They found that the obese 
twins had higher fasting insulin levels and lower glucose tolerance than the normal 
weight twins. Hyperinsulinemia and insulin resistance create metabolic changes that can 
lead to type II diabetes, among other diseases (Pi-Sunyer, 1993). The positive correlation 
between BMI and the risk of developing type II diabetes is clearly illustrated by a study 
conducted in 1995 by Colditz and colleagues. These researchers demonstrated that 
women with a BMI of 35 kg/m2 or more had a 93 times greater risk of developing 
diabetes than those with a BMI of less than 22 kg/m2. Though BMI is a strong predictor 
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of diabetes, abdominal obesity, measured by waist-to-hip ratio (WHR), may be a better 
predictor than BMI alone. Ohlson, Larsson, and Svardsudd (1985) followed a cohort of 
54-year-old men for a period of 13.5 years and separated them into tertiles of BMI and 
WHR. They found that the men in the lowest tertile of WHR did not have an increased 
risk of developing diabetes, even when they were in the highest tertile of BMI.    
 Hypertension and Cardiovascular Disease. The risk of hypertension rises 
significantly with increasing BMI (Redon, 2001). Total blood volume in the body 
increases proportionate to body weight in order to meet the oxygen demands of lean and 
adipose tissue. Thus, obesity commonly augments the body’s total blood volume, which 
requires increased cardiac output (i.e., the volume of blood expelled from the left 
ventricle of the heart in one minute) primarily through greater stroke volume (i.e., the 
volume of blood pumped from one ventricle of the heart with each beat; Poirer, 2006). 
The increase in stroke volume and cardiac output is associated with structural changes in 
the heart, including left ventricular dilation and hypertrophy (i.e., enlargement of muscle 
tissue that makes up the heart wall; Lauer, 1991), which is associated with congestive 
heart failure. In addition to the relationship between obesity, hypertension, and the 
associated changes in cardiac structure and function, the incidence of coronary heart 
disease is disproportionately high in obese individuals (Kopelman, 2000).  
 Cancer. Obesity is associated with increased risk of death from cancer. In a study 
of 750,000 people, men who were at least 40 % overweight were 55 % more likely to die 
from colorectal and prostate cancer than those at normal weight, and women who were at 
least 40 % overweight were 33 % more likely to die from endometrial, cervical, uterine, 
ovarian, gallbladder, and breast cancer than those at a normal weight (Garfinkel, 1985). 
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Further evidence for an association between obesity and risk of death from cancer in 
women was elucidated in an investigation conducted by Manson et al. (1995). They 
found that women with a BMI of at least 32 kg/m2 were twice as likely to die from cancer 
than women with a BMI less than 19 kg/m2.  
Obstructive Sleep Apnea Syndrome 
Obstructive sleep apnea syndrome (OSAS) is a common sleep-related breathing 
disorder characterized by repetitive episodes of upper airway collapse during sleep, 
which result in partial (hypopnea) and complete (apnea) occurrences of breathing 
cessation. Apnea and hypopnea events are generally stopped by arousals from sleep 
(AASM). The lack of airflow typically causes oxygen desaturation, and can lead to an 
increase in PaCO2 in cases of extended events. Individuals presenting with OSAS 
frequently report excessive daytime sleepiness, cognitive performance problems, and 
decline in their overall quality of life (Engleman & Douglas, 2004), and it is hypothesized 
that these symptoms are related to repeated arousals from sleep and intermittent 
hypoxemia (American Academy of Sleep Medicine, 1999).    
The signs and symptoms of OSAS include the following: excessive daytime 
sleepiness, choking or gasping during sleep, recurrent arousals from sleep, unrestful 
sleep, and cognitive problems. The essential diagnostic criterion for OSAS is an 
overnight sleep monitoring test that demonstrates an apnea-hypopnea index of five or 
more. Apneas are characterized by a cessation of airflow that lasts at least 10 seconds. 
Hypopneas are defined as a significant reduction in airflow (>50 %), or moderate 
reduction in airflow (<50 %) with evidence of oxygen desaturation (> 3 %) or arousal, 
and the event lasts at least 10 seconds. The level of OSAS severity is determined by two 
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factors: the intensity of the individual’s daytime sleepiness and the results of the 
overnight laboratory monitoring, specifically the apnea hypopnea index (American 
Academy of Sleep Medicine, 1999).   
Prevalence and Etiology. OSAS affects 2 % of middle-aged women and 4 % of 
middle-aged men in the United States (Young et al. 1993). Obesity is present in 
approximately 70 % of individuals with OSAS and is considered the most prominent, and 
only reversible risk factor. Though the underlying mechanisms of the association between 
obesity and OSAS are somewhat unclear, it is hypothesized that increased weight 
decreases the size of the upper airway, and thus, increases the propensity for apnea 
events. While obesity is the most common risk factor for OSAS, several other 
contributors have been identified, including male sex, being over the age of 65 years, 
post-menopausal status in women, African American race, and certain lifestyle choices 
(i.e., smoking and alcohol use; Malhotra & White, 2002).  
Treatment. Oral appliances and surgical procedures are successful OSAS 
treatment options in some cases; however, the majority of patients do not receive 
sufficient clinical benefit from these approaches (Veasey et al., 2006). Continuous 
positive airway pressure (CPAP) is considered the most consistently effective and 
preferred treatment for OSAS (Gay et al., 2006). CPAP is comprised of a mask with a 
harness that fits over the head, a flexible tube, and a pump that provides continuous 
positive air pressure. The steady positive air pressure to the upper airway keeps it from 
collapsing during sleep, which typically reduces substantially or completely eliminates 
nocturnal respiratory disturbances, and thus, reduces sleep fragmentation and nocturnal 
hypoxemia (American Thoracic Society, 1994). Despite the effectiveness of CPAP 
 17 
treatment, it is approximated that 25 - 50 % of persons with OSAS will refuse CPAP 
treatment or will not tolerate it (Zozula & Rosen, 2001).  
In their review of alternative and/or supplemental approaches to treating OSAS, 
Veasey et al. (2006) found that a sufficient degree of weight loss, through dietary 
modification, can result in substantial improvement in overweight and obese persons with 
OSAS. Thus, they concluded that weight loss should be regularly recommended for the 
majority of overweight and obese patients with OSAS. However, they recognized that 
significant advances in dietary weight loss programs are necessary. Bariatric surgery can 
be an effective treatment option for some morbidly obese patients with OSAS; however, 
it can result in serious and potentially fatal complications (Veasey et al., 2006). 
Obstructive Sleep Apnea and Neurocognitive Impairment 
General Cognitive Functioning. General cognitive functioning can be 
conceptualized as a global entity comprised of abilities that span across multiple 
cognitive domains (Strauss, Sherman, & Spreen, 2006). Assessment of general cognitive 
functioning typically includes tests of general intelligence, or the intelligence quotient 
(IQ), which Wechsler (1944) defined as “the capacity to act purposefully, to think 
rationally, and to deal effectively with the environment” (p. 3). Comprehensive batteries 
assessing general intelligence are widely used; however, they can be time consuming. 
Thus, measures that estimate intelligence, as well as global cognitive screening measures, 
are also used to assess general cognitive functioning throughout the existing literature 
pertaining to OSAS and cognitive functioning.  
 The impact of OSAS on general intellectual functioning is not conclusive in the 
literature. Several studies have demonstrated that general intellectual functioning is 
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spared (Greenberg et al., 1987; Kales et al, 1985; Knight et al., 1987; Redline et al., 
1997). However, others have identified relationships between OSAS and indicators of 
general intelligence (Bédard et al., 1991; Bédard 1993; Berry et al., 1990).  
 In a study conducted by Kales et al. (1984), the researchers found that 76 % of 
the 50 participants with severe sleep apnea showed cognitive impairment in one or more 
domain. However, they did not exhibit impaired overall intellectual functioning, as 
measured by the Wechsler Adult Intelligence Scale Revised (WAIS-R; Wechsler, 1981), 
compared to normative data. Moreover, in case-controlled studies completed by 
Greenberg, Watson, and Deptula (1987) and Redline et al. (1997) no differences were 
observed between persons with OSAS and matched controls on estimates of the WAIS-R 
(1981) Full-Scale Intelligence Quotient (FSIQ).  
 While there is some evidence that OSAS does not impact general intellectual 
functioning, a study conducted by Bédard et al. (1991) suggested otherwise. These 
investigators observed that participants with severe OSAS exhibited deficits on the 
WAIS-R FSIQ and Performance IQ compared to matched controls.  Moreover, they 
observed that participants with severe OSAS demonstrated greater deficits on the FSIQ, 
Verbal IQ, and Performance IQ compared to participants with moderate OSAS. 
Additionally, reductions in general intellectual functioning were attributable to the 
severity of participants’ hypoxemia, as opposed to daytime vigilance. Similar results 
were observed in a correlational study conducted by Berry et al. (1986). Results from this 
study indicated that severity of nocturnal hypoxemia was associated with Verbal and 
Performance IQ, such that increasing hypoxemia severity related to decreased 
performance on these measures.  
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 In a subsequent study, Bédard et al. (1993) found no differences between patients 
with OSAS and matched controls on the WAIS-R FSIQ or Verbal IQ. However, they 
reported lower Performance IQ scores among the OSAS patients who were not treated 
with continuous positive airway pressure (CPAP) compared to those who were. 
Therefore, this study suggests that OSAS patients may not demonstrate global intellectual 
impairment compared to normal controls, but following CPAP treatment may show 
within-subjects improvement. This phenomenon is supported in the literature by other 
studies that have found improvements in general intellectual functioning following CPAP 
treatment (Engleman & Douglas, 1993; Engleman et al., 1994; Klonoff, 1987; 
Montplaisir, 1992).  
 Overall, the research regarding the relationship between OSAS and general 
intellectual functioning is mixed. There is some evidence to suggest that OSAS is 
associated with decrements in general intelligence; however, this has not been 
consistently observed. In the studies that have demonstrated associations between OSAS 
and general intelligence, apnea severity, specifically nocturnal hypoxemia, appears to be 
negatively correlated with intellectual ability. Further, despite the mixed data concerning 
between subjects differences in global intellectual functioning, there is some evidence 
supporting within-subjects improvements in this cognitive domain following CPAP 
treatment.  
 Attention. Attention consists of a complex network of elements with multiple 
underlying processes that allow persons to filter relevant and irrelevant information 
(Strauss, et al., 2006). The processes that underlie attention include sensory selection 
(e.g., filtering and focusing), response selection (e.g., response initiation and inhibition), 
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attentional capacity (e.g., arousal and effort), and sustained performance (e.g., vigilance 
and exhaustibility; Cohen, 1993). Further, attention can be conceptualized as consisting 
of distinct aspects, including selective attention, sustained attention, and divided 
attention. Attentional dysfunction can manifest as a variety of deficits in one or more of 
these components (Strauss et al., 2006).   
 Attentional functioning is the most commonly assessed cognitive domain in the 
study of OSAS, and it also appears to be the most consistently impacted in patients with 
OSAS (Aloia et al., 2004). In their meta-analysis of case-controlled and norm-referenced 
data, Beebe and colleagues (2003) determined that OSAS markedly impairs vigilance, 
showing a very large effect size (1.40) in case-controlled data. Several case-controlled 
studies have found deficits in attention/concentration (Bédard et al., 1991; Bédard et al., 
1993; Findley et al., 1986; Greenberg et al., 1987; Naegele et al., 1995; Redline et al., 
1997) and vigilance (Bédard et al., 1991; Bédard et al., 1993; Ferini-Strambi et al., 2003; 
Findley et al., 1986; Munoz et al., 2000; Redline et al., 1997) in patients with OSAS 
compared to normal controls. Bédard et al. (1991) analyzed the impact of OSAS severity 
on attention and vigilance, and observed that the level of OSAS severity may 
differentially impact vigilance performance. They found that patients with severe OSAS 
showed greater deficits in vigilance than those with moderate OSAS. Similarly, Naegele 
et al. (1995) showed that sleep fragmentation, as measured by the number of apnea 
episodes per hour of sleep, correlated with performance on tests of 
attention/concentration, but nocturnal hypoxemia did not.   
 Multiple case-controlled studies have demonstrated the impact of OSAS on 
attentional functioning; the effect of CPAP treatment on this cognitive domain is also 
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well documented in the literature. A number of studies have demonstrated that CPAP 
treatment improves attention/concentration (Bédard et al., 1993; Borak et al., 1996; 
Engleman et al., 1994; Naegele et al., 1998; Montplaisir et al., 1992; Valencia-Flores et 
al., 1996) and vigilance (Engleman et al., 1993; Ferini-Strambi et al., 2003; Munoz et al., 
2000). The majority of these studies conducted follow-up assessments 6-to-12-months 
after collecting baseline data; however, some studies suggest that even short term CPAP 
treatment improves attentional functioning. Ferini-Strambi et al. (2003) conducted a 
study in which they evaluated the effectiveness of short-term and long-term CPAP 
treatment on cognitive functioning. They observed that after only 15 days of CPAP 
treatment, OSAS patients’ vigilance improved. Moreover, in a placebo-controlled 
crossover study, Engleman et al. (1994) found that CPAP treatment improved vigilance 
and attention in a relatively short amount of time (4 weeks) compared to placebo.  
 Though research suggests short term CPAP treatment improves vigilance and 
attention, it may require more than one week of treatment to be effective, as evidenced by 
a study conducted by Bardwell et al. (2001). These researchers assessed the effect of one 
week of CPAP treatment on the cognitive functioning of persons with OSAS. They 
observed that one week of treatment improved overall cognitive functioning compared to 
placebo; however, benefits in specific cognitive domains, including attention/vigilance 
were not found. Thus, while CPAP treatment can improve vigilance in as little as 15 
days, one week of CPAP treatment does not appear to be sufficient for improving 
attentional functioning in patients with OSAS.  
 CPAP treatment also failed to show improvements in attentional functioning in a 
study conducted by Monasterio et al. (2001). These researchers examined the 
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effectiveness of CPAP treatment compared to conservative treatment (i.e., sleep hygiene) 
in patients with mild OSAS. The CPAP group showed greater improvements in clinical 
symptoms of OSAS at 3 and 6-month follow-ups, but significant differences were not 
observed on measures of cognitive functioning, including attention/vigilance. These 
results differ from most other studies suggesting attention/vigilance improves following 
CPAP treatment. This discrepancy could be due to the fact that OSAS patients’ baseline 
values for neurocognitive functioning were normal, as opposed to the majority of other 
studies in which impaired baseline values were observed.   
Taken together, the literature suggests a clear relationship between OSAS and 
decrements in attention and vigilance. Additionally, some research has highlighted a 
relationship between apnea severity, specifically sleep fragmentation, and impaired 
attention and vigilance. CPAP treatment has consistently demonstrated efficacy in 
ameliorating attentional deficits and can be effective after a brief amount of time.   
 Executive Functions. Strauss et al. (2006) described executive functions as a set 
of complex processes mediated by the frontal lobes of the brain. Broadly, they allow 
persons to respond adaptively to their environment, particularly in novel situations. 
Executive dysfunction can manifest as a collection of problems in everyday life, such as 
difficulty with decision-making, problems following through and shifting plans, difficulty 
in circumstances involving different aspects of memory (e.g., remembering to carry out a 
goal- directed activity at a later time), and poor organizational ability, among others. 
 In their meta-analysis, Beebe et al. (2003) found that the domain of executive 
functioning is substantially impacted by OSAS. These investigators’ analyses 
demonstrated moderate to large mean effect sizes (.53 in norm-referenced data and .73 in 
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control-referenced data) for this cognitive construct. While this meta-analysis suggests a 
clear relationship between OSAS and executive functioning, it is difficult to determine 
the specific meaning of this finding as the methods used to assess this domain vary 
considerably across studies (Décary et al., 2000). Aloia et al. (2004) acknowledged that 
several different tests are accepted as measures of executive functioning; however, each 
assesses a different component of the multiple functional systems within the frontal lobes 
of the brain. Therefore, although reviews and meta-analyses highlight the associations 
between OSAS and executive functioning (Aloia et al., 2004; Beebe et al., 2003), they do 
not elucidate the distinct “functions” affected within this cognitive domain.  
 In case-controlled studies conducted by Bédard et al. (1991) and Naegele et al. 
(1995), individuals with OSAS were characterized by deficits in various areas of 
executive functioning compared to normal controls. Naegele et al. (1995) found that 
OSAS patients demonstrated deficits on a modified Wisconsin Card Sorting Test 
(WCST; Nelson, 1976) and the Tower of “Toronto” (Saint-Cyr, Taylor, & Lang, 1988), 
which assess working memory and planning abilities, respectively. They also reported 
that errors on the modified WCST were related to the level of nocturnal hypoxemia. 
Bédard et al. (1991) reported significant differences between OSAS patients and normal 
controls on many different executive functioning assessments, including those that 
measure working memory, set shifting, and verbal fluency. They also observed that 
executive functioning deficits were attributable to the severity of nocturnal hypoxemia.  
 Among other studies that have addressed the construct of executive functioning, 
associations have been observed between OSAS and planning difficulties (Greenberg et 
al., 1987), verbal fluency (Salorio et al., 2002), and set shifting in the face of error (Lee et 
 24 
al., 1999). Redline et al. (1997) reported that patients with mild OSAS performed 
significantly more poorly on tests of working memory than controls. However, working 
memory deficits were not observed in studies conducted by Lee et al. (1999) and Salorio 
et al. (2002). This inconsistency regarding deficits in working memory could be related to 
the fact that Redline et al. (1997) assessed working memory with the Digits Backwards 
Test from the WAIS-R, whereas, Lee et al. (1999) and Salorio et al. (2002) used the 
WCST. 
 It is unclear from the literature whether or not deficits in executive functioning 
improve following CPAP treatment. Some evidence suggests that while CPAP improves 
certain cognitive deficits associated with OSAS, executive functioning continues to be 
adversely impacted following treatment (Bédard et al., 1993; Ferini-Strambi et al., 2003; 
Valencia-Flores et al., 1996; Montplaisir et al., 1992). These investigators argued that the 
lack of treatment response in functions mediated by the frontal lobes of the brain may be 
the result of irreversible anoxic brain damage caused by nocturnal hypoxemia. However, 
this is not a conclusive argument in light of contradictory evidence: A number of studies 
have observed that executive functioning does improve following CPAP treatment 
(Borak et al., 1996; Engleman et al., 1994; Engleman et al., 1997; Naegele et al., 1998).  
By and large, the literature suggests a relationship between OSAS and impaired 
executive functioning. However, given the variability across studies in the assessments 
used to analyze this relationship, the specific aspects of executive functioning that OSAS 
affects are unclear. There is some evidence to suggest that deficiencies in this cognitive 
domain are related to nocturnal hypoxemia, as opposed to sleep fragmentation. Several 
investigators have found that executive functions remain impaired following CPAP 
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treatment, which suggests that OSAS may cause irreversible anoxic brain damage. 
However, other researchers have observed that executive functions improve following 
CPAP treatment. Again, this lack of consistency could be the result of lack of 
standardization across studies in assessments used to analyze this cognitive domain.  
 Memory. Memory is a general term that refers to a complex set of processes in 
which individuals encode, store, and retrieve information. Models of memory typically 
divide the domain into long-term memory (LTM) and short-term memory (STM). LTM 
refers to the permanent or long-term storage of information, whereas STM refers to the 
brief (i.e., seconds), temporary storage of information. Current models of memory 
include working memory into the construct of STM. Working memory is a limited-
capacity store that allows information to be temporarily held and manipulated. Memory 
dysfunction can occur following injuries or disorders of the brain that either directly 
impact regions of the brain involved in memory, or brain systems not directly related to 
memory, but associated with memory functioning (e.g., attention; Strauss et al., 2006). 
 Like executive functioning, the methods used to assess memory differ markedly 
across studies (Aloia et al., 2004). Beebe et al. (2003) determined that the impact of 
OSAS on memory functioning is inconsistent in the literature, and concluded that their 
mixed meta-analytic results were likely due to methodological problems (i.e., test 
selection) and inconsistency across studies regarding what specific aspects of memory 
were tested (i.e., initial learning, storage, retrieval, etc.) Though the literature may not be 
clear regarding the unique aspects of memory impacted by OSAS, in general, patients 
with OSAS perform more poorly on tests of memory compared to normal controls (Aloia 
et al., 2004).  
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 Several studies have highlighted deficiencies in long-term memory (LTM) in 
persons with OSAS (Bédard et al., 1991; Berry et al., 1986; Findley et al., 1986; Naegele 
et al., 1995; Kales et al., 1985). These studies demonstrated that patients with OSAS have 
deficits in the delayed recall of visual and verbal information. Bédard et al. (1991) also 
found deficits in OSAS patients in both immediate and delayed recall on a measure of 
visuo-spatial constructional ability and visual memory. While Findley et al. (1986) found 
that poor performance on immediate recall of verbal and visual information was related 
to levels of nocturnal hypoxemia, others have observed that these memory deficiencies 
are related to daytime vigilance (Kales et al., 1985; Bédard et al., 1991).   
 The majority of studies have reported deficits in the delayed recall of visual and 
verbal information among patients with OSAS. However, Neagele et al. (1995) 
contended that the “forgetting curve” could not be accurately interpreted without first 
considering whether or not the initial learning of information differed between 
participants. Therefore, these investigators implemented procedures that allowed them to 
equalize the amount of learning across participants and assess the amount of forgetting 
per se. They found that OSAS patients do not have “forgetting disabilities,” but rather, 
that their LTM deficits are associated with learning impairment. 
 Though several studies have analyzed the impact of OSAS on LTM, fewer have 
assessed its affect on short-term memory (STM). Kales et al. (1985) found that 50 % of 
the 22 (total N = 50) participants with OSAS who completed the Wechsler Memory Scale 
(WMS; Wechsler, 1945) were impaired. Further, the investigators reported that of the 
entire sample that completed either the WMS, WAIS (Wechsler, 1955), or WAIS-R, 46 
% of the participants demonstrated impaired STM and 32 % demonstrated impairments in 
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LTM. Naegele et al. (1995) reported poorer verbal and visual STM performance in 
patients with OSAS compared to normal controls. Moreover, through regression 
analyses, these investigators found that when patients were divided according to markers 
of severity of OSAS (i.e., number of apneas and hypopneas each hour during sleep and 
level of nocturnal hypoxemia), Digit Span and Visual Span predicted severity under the 
apnea-hypopnea index division, whereas only the Digit Span predicted severity under the 
hypoxemia division. Therefore, these results suggest that patients with severe OSAS 
perform poorly on the digit span, regardless of markers used to categorize their severity. 
 Borak et al. (1996) found that CPAP treatment improved visual, spatial, and 
recent verbal memory, as measured by the Benton Visual Retention Test (BVRT; Benton, 
1968) and Rey Auditory Verbal Learning Test (RAVLT; Rey, 1958), respectively. These 
improvements were observed after only three months of CPAP treatment. Further, 
Bédard et al. (1991) reported improvements in immediate and delayed verbal memory 
after 6 months of CPAP treatment. Naegele et al. (1998) demonstrated that after 6 months 
of CPAP treatment, OSAS patients’ learning disabilities improved; however, their short-
term verbal and visual memory deficits remained unchanged. Engleman and Douglas 
(1993) and Engleman et al. (1997) also failed to observe differences in memory following 
4 weeks of CPAP treatment, despite improvements in other areas of cognitive 
functioning. Naegele et al. (1998) suggested that the lack of improvement in short-term 
memory might be due to the accumulated pathogenic effect of sleep fragmentation and 
hypoxemia on the brain.    
 In a study conducted by Valencia-Flores et al. (1996) OSAS patients completed 
an alertness Multiple Sleep Latency Test and a brief neuropsychological assessment prior 
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to, and immediately following one night of CPAP treatment in a sleep lab. These 
investigators observed that performance on the RAVLT increased for participants with 
increased alertness, but decreased for those with decreased alertness. Thus, the authors 
concluded that some of the memory deficits associated with OSAS that are moderated by 
vigilance may be immediately reversible following CPAP treatment.  
Taken together, the literature suggests that OSAS is related to memory 
decrements. However, it is not clear what specific aspects of memory are affected; this is 
likely a result of the divergent methods used across studies to assess this cognitive 
construct. The literature points to relationships between OSAS and impaired long-term 
visual and verbal memory, and there is some evidence to suggest that this relationship is 
due to learning impairment rather than forgetting disabilities. There also appears to be an 
association between OSAS and impaired short-term visual and verbal memory. The 
research is mixed regarding whether or not memory improves following CPAP treatment. 
Further, the relationship between impaired LTM and markers of apnea severity is not 
clear as it has been attributed to both nocturnal hypoxemia and sleep fragmentation in the 
literature.    
 Motor Functions. Many neurological disturbances involve impaired motor 
performance; therefore, tests of motor functioning are typically included in 
neuropsychological assessments (Strauss et al., 2006). Motor performance tests generally 
assess different aspects of handedness, including speed and dexterity. Deficits in motor 
ability can have a large impact on an individual’s functional capacity, and can result in 
negative outcomes in the areas of employment and social functioning (Strauss et al., 
2006).  
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 Aloia et al. (2004) found that the majority of studies in their review that 
investigated the relationship between OSAS and motor functions reported impairments in 
persons with OSAS (Aloia et al., 2004). Based on their review, impairments in OSAS 
patients’ motor functions appear to impact motor coordination, as opposed to motor 
speed. Similarly, in their meta-analysis, Beebe et al. (2003) reported that OSAS markedly 
impacted fine-motor coordination, but affected motor speed to a much lesser degree.   
 Several studies have used the Purdue Pegboard Test (Tiffin, 1968) to assess 
motor coordination in patients with OSAS (Bédard et al., 1991; Bédard et al., 1993; 
Greenberg et al., 1987). Greenberg et al. (1987) reported persons with OSAS performed 
significantly poorer on the Purdue Pegboard Test compared to normal controls. 
Additionally, they found that hypoxemia severity was correlated with deficits on the 
motor coordination task.  
 Bédard et al. (1991) reported similar results. In this study, the investigators 
compared normal controls to groups of patients with moderate and severe OSAS. The 
investigators reported statistically significant differences between all groups, such that 
moderate and severe OSAS patients performed poorer than normal controls, and severe 
OSAS patients performed poorer than moderate OSAS patients. Moreover, they reported 
that reductions in motor coordination were attributable to the severity of hypoxemia.  
 In their study of neuropsychological dysfunction in OSAS patients before and 
after CPAP treatment, Bédard et al. (1993) observed that motor coordination was 
impaired in OSAS patients at baseline compared to normal controls. Additionally, they 
reported that motor coordination continued to be impaired following CPAP treatment. 
These investigators argued that hypoxemia may result in irreversible anoxic brain 
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damage, which may contribute to the persistent deficits in this domain of functioning. 
Further, they contended that since the cognitive deficits found to be irreversible (e.g., 
motor coordination) are already apparent in patients with moderately severe OSAS 
(Bédard et al., 1991), individuals with this disorder need to be treated at an earlier stage 
of OSAS severity in order to avoid irreversible deficits in functioning.  
Overall, the literature points to a relationship between OSAS and impaired motor 
coordination. Multiple investigators have observed associations between impaired motor 
coordination and nocturnal hypoxemia. Additionally, there is evidence to suggest that 
motor coordination decrements do not improve following CPAP treatment. Thus, it is 
possible that the enduring problems with motor coordination observed in OSAS patients 
are due to irreversible anoxic brain damage.  
 Neuropathological Mechanisms. Fragmented sleep and nocturnal hypoxemia 
contribute to the cognitive deficits observed in patients with OSAS; however, research 
suggests that these factors are differentially related to the neuropsychological sequelae 
associated with the disorder. While sleep fragmentation seems to be closely associated 
with attention (Bédard et al., 1991; Naegele et al., 1995) and memory (Bédard et al., 
1991; Findley et al., 1986), nocturnal hypoxemia appears to be related to general 
intellectual functioning (Findley et al., 1986; Montplaisir et al., 1992), executive 
functioning (Montplaisir et al., 1992; Naegele et al., 1995), and motor coordination 
(Bédard et al., 1991; Bédard et al., 1993; Greenberg et al., 1987; Montplaisir et al., 1992).  
 Despite some evidence regarding the differential effects of sleep fragmentation 
and nocturnal hypoxemia on the cognitive deficits associated with OSAS, there is not a 
conclusive model among investigators regarding the pathogenesis of such deficiencies 
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(Aloia et al., 2004). However, changes in vascular function appear to be involved in the 
underlying processes. Lanfranchi and Somors (2001) argued that the hypoxemia 
experienced in OSAS results in increased vasodilatation and decreased vascular 
protective processes, which can eventually lead to changes in the structure and function 
of blood vessels. Indeed, others have observed relationships between OSAS severity and 
small vessel white matter disease (Aloia et al., 2001; Colrain et al., 2002), which is 
typically seen in persons with high blood pressure and type II diabetes. Though there is 
evidence to support the association between OSAS and aberrant vascular changes, it is 
unclear how those alterations impair specific domains of cognitive functioning.   
Obesity and Neuropsychological Dysfunction 
General Cognitive Functioning. Studies that have examined the impact of 
obesity on general intellectual functioning are largely nonexistent. Many investigators 
have used subtests from the WAIS (Wechsler, 1955) and WAIS-R (Wechsler, 1981) to 
measure different aspects of neurocognitive abilities in obese persons, but they have not 
examined their general intelligence specifically. However, there is one study in the extant 
literature that assessed this relationship. Chelune et al. (1986), investigated relationships 
between obesity and Full-Scale IQ scores on the WAIS (Wechsler, 1955). These 
researchers reported that their sample was of average intelligence, with scores distributed 
in a pattern similar to the general population. Thus, there is limited evidence to suggest 
that obesity is not related to deficits in general intelligence, but considering the overall 
lack of empirical inquiry, this relationship remains unclear.    
Though the association between obesity and intelligence is uncertain, there is 
some evidence to suggest that obesity may be related to global cognitive impairment, 
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particularly in aging populations (Gunstad et al., 2010; Jeong et al.; 2005). Gunstad et al. 
(2009) analyzed global cognitive function with the Mini-Mental State Examination 
(MMSE; Folstein, 1975) and the Blessed Information-Memory-Concentration Test (IMC; 
Blessed, Tomlinson, & Roth, 1968) in their study of 1,703 individuals (aged 19 to 93 
years) from the Baltimore Study of Aging. Using cross-sectional analyses, these 
investigators found that higher BMI was associated with poorer performance on both the 
MMSE and Blessed IMC, and higher waist-circumference (WC) and waist-to-hip ratio 
(WHR) were associated with poorer performance on the Blessed IMC. Their longitudinal 
analyses showed that BMI did not interact with age on either test of global cognitive 
functioning. However, WC and WHR did interact with age, and were related to poorer 
performance on the Blessed IMC over time. Joeng et al. (2005) reported similar results in 
their study of 467 individuals (ages 65 years and older). These researchers assessed 
global cognitive functioning using the Korean MMSE (K-MMSE; Kang, Na, & Hahn, 
1997). Their results indicated abdominal obesity, as measured by WC, was strongly 
associated with poor cognition with increasing BMI.  
Overall, the impact obesity has on general intellectual functioning is not clear due 
to the lack of research into this relationship. The extremely limited data available on this 
topic suggests that the two may not be correlated. There is, however, an increasing body 
of evidence that illuminates the relationship between obesity and global cognitive 
impairment in aging populations. Further, abdominal obesity appears to be a salient risk 
factor for global cognitive impairment in the elderly.  
Attention. Research concerning the relationship between obesity and attention 
deficits has yielded mixed results. Altfas (2002) conducted a study in which the clinical 
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records of 215 patients seeking obesity treatment were reviewed. The author reported that 
27.4 % of the sample had Attention Deficit Hyperactivity Disorder (ADHD), and 42.6 % 
of the extremely obese participants (i.e., those with a BMI greater than or equal to 40 
kg/m2) had ADHD. The author argued that ADHD was highly prevalent among obese 
persons, especially those who met the criterion for morbid obesity. Though these results 
are compelling, the study had several methodological limitations. First, the results lack 
external validity, as 90 % of the sample consisted of middle-aged women. Second, the 
author based the diagnosis of ADHD on information in the patients’ medical records, but 
not standardized interviews and cognitive testing. Finally, the author did not specify if he 
controlled for other psychiatric or medical conditions in the analyses that could have 
confounded the results.  
Results from the Altfas (2002) study have not been replicated. On the contrary, 
some studies have reported no impairments in attention among obese persons. For 
example, Elias et al. (2003) used the Digit-Span Forward Subtest from the WAIS 
(Wechsler, 1955) to analyze this relationship, and found no associations between obesity 
and performance on this test with the following covariate set: age, education level, 
occupation, mean alcohol consumption, mean cigarette smoking, mean total cholesterol, 
and type II diabetes. Additionally, their multiple linear regression models combining 
obesity and hypertension yielded no significant effects for attention.  
Elias et al. (2005) also used the Digit-Span Forward Subtest from the WAIS 
(Wechsler, 1955) to assess this domain of cognitive functioning among persons with 
obesity and/or type II diabetes. These researchers reported statistically significant, but 
weak, negative correlations for the performance of obese men and women on this test 
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with the covariates of age and cardiovascular risk factors. However, these associations 
were no longer significant for men or women when the covariates of education, 
occupation, and native language were included in the model.     
In their prospective cohort study of 2,223 healthy individuals aged 32 to 62 years 
at baseline, Cournot et al. (2006) observed a relationship between obesity and attention. 
These investigators reported that at baseline women performed significantly more poorly 
on a selective attention test (adapted from the Sternberg test; Sternberg, 1975) as BMI 
increased when adjusting for age, educational level, diabetes, systolic blood pressure, and 
perceived health.  However, this relationship was not observed in men. Additionally, they 
found that larger BMI changes in women were related to poorer performance on the 
selective attention test at follow-up. However, in their longitudinal analyses, after 
adjusting for age, region of residence, education level, baseline cognitive score, and 
medical or psychosocial confounders, the association between BMI and progression of 
attention deficit was no longer significant, and they did not observe any interaction 
between BMI and gender.    
Gunstad et al. (2010) found divergent results in their study of obesity and 
cognitive functioning. These researchers assessed attention with the Trail Making Test-A 
(TMT-A; Reitan, 1992). In their cross-sectional analyses, higher BMI, WC, and WHR 
were associated with faster performance on the TMT-A. Further, their longitudinal 
analyses demonstrated that increasing obesity was associated with faster performance on 
the TMT-A as age increased. The investigators offered two potential explanations for 
these somewhat counterintuitive findings. First, the cognitive impact of intentional 
dieting could have impacted the performance of those participants at normal and low 
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weights. However, the researchers were not able to confirm this hypothesis, as data 
regarding participants’ dieting status were not available. Second, the long-term affect of 
obesity on cognitive functioning may be partially determined by a person’s weight across 
the lifespan.  
In summary, several researchers have examined the relationship between obesity 
and attention, but results have varied significantly across studies. Though multiple studies 
have found significant relationships between BMI and attentional impairments, these 
relationships were not significant when covariates (e.g., education, sex, cardiovascular 
risk factors) were included in the models. One study found that obesity was related to 
increased attention with age; however, the underlying mechanisms for this relationship 
are uncertain. Thus, the affect of obesity on attentional functioning is unclear in the 
literature.  
Executive Functions. Several studies have highlighted relationships between 
obesity and deficits in executive functioning. Gunstad et al. (2007) conducted a study that 
examined the executive functioning of 408 healthy individuals across the adult life span 
(20 to 82 years). After controlling for potential confounding variables, these investigators 
observed that overweight and obese persons (BMI greater than or equal to 25 kg/m2) 
demonstrated poorer performance on tests of executive functioning (i.e., verbal fluency 
and planning/rule learning) than normal weight individuals (BMI of 18.5 - 24.9 kg/m2). 
Gunstad et al. (2010) conducted a similar study in which they analyzed the relationships 
between obesity indices (i.e., BMI and WHR) and cognitive functioning in 1,703 persons 
from the Baltimore Longitudinal Study of Aging. Though cross-sectional analyses 
showed that no associations emerged for obesity indices and an executive functioning 
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task (i.e., cognitive flexibility), longitudinal analyses demonstrated that higher WHR was 
associated with poorer performance on the task as age increased. Thus, these results 
suggest that obesity produces detrimental effects on executive functioning as age 
increases.  
Studies of neurocognitive functioning in morbidly obese persons provide 
additional evidence for the impact of obesity on executive functioning. Chelune et al. 
(1986) reported that 50 % of their sample (N = 44) of morbidly obese patients electing for 
bariatric surgery demonstrated impaired higher-level cognitive problem solving abilities. 
Additionally, they found that 21 % of patients showed impaired cognitive flexibility. 
However, they did not consider confounding health factors associated with obesity (i.e., 
type II diabetes, cardiovascular disease, OSAS) that could have concomitantly influenced 
patients’ performance on these measures. In a more thorough study, Boeka and Lokken 
(2008) demonstrated that morbidly obese individuals seeking bariatric surgery exhibited 
impaired executive functioning on tests of planning, problem solving, and mental 
flexibility. Moreover, they did not find significant differences between morbidly obese 
patients with and without co-occurring health conditions. Taken together, results from 
these studies highlight the relationship between morbid obesity and executive functioning 
impairment.   
Waldstein and Katzel (2006) assessed the interactive relationships between 
obesity indices, blood pressure (BP), and executive functioning performance. In their 
analyses if 90 healthy, middle-aged and older adults (54 - 81-years-old), they found that 
individuals with higher BMI and WHR and higher BP performed the most poorly on an 
executive functioning task that measured response inhibition. However, this relationship 
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was not observed on a mental flexibility test. These results suggest that the combination 
of greater WHR and BMI and higher BP has a detrimental effect on executive 
functioning, specifically, response inhibition.  
Overall, the literature suggests a clear connection between obesity and executive 
functioning deficits. Further, this relationship has been observed after controlling for 
other potential risk factors (e.g., diabetes, hypertension, OSAS); thus, suggesting obesity 
is an independent risk factor for deficits in executive functions. The specific aspects of 
executive functioning affected appear to be verbal fluency, planning, problem solving, 
and mental flexibility. Some evidence suggests that WHR is associated with impaired 
executive functioning as age increases. Further, hypertension may moderate this 
relationship, such that increasing WHR and blood pressure result in poorer executive 
functioning performance.    
Memory. The majority of studies that have analyzed the relationship between 
obesity and memory have observed impaired memory in obese persons (Cournot et al., 
2006; Elias et al., 2003; Elias et al., 2005; Gunstad et al., 2006; Gunstad et al., 2010), 
specifically, in their visual and verbal memory abilities. Only one study in the extant 
literature found no relationship between obesity and impaired memory performance 
(Boeka & Lokken, 2008).  
Elias et al. (2003) conducted a study in which they aimed to identify the 
independent effects of obesity and hypertension on cognitive functioning. These 
investigators included the Logical Memory (immediate and delayed recall), Visual 
Reproductions, and Paired Associates subtests from the WMS-III (Wechsler, 1997) in 
their assessment of memory. In this prospective study of 1,423 participants from the 
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Framingham Heart Study, the researchers found that obese men performed significantly 
more poorly than non-obese men on the Logical Memory and Visual Reproductions 
subtests when covariates (i.e., age, education, occupation, alcohol consumption, cigarette 
use, total cholesterol, type II diabetes) were included in the model. However, there were 
no significant obesity effects for women. In the combined hypertension and obesity 
model, hypertensive obese men showed significantly poorer performance on the Logical 
Memory and Visual Reproductions subtests than men who were either obese or 
hypertensive. Elias et al. (2005) carried out a similar study in which they examined both 
the independent effects of obesity on cognitive functioning, as well as the interactions 
between obesity and type II diabetes in the same cohort of individuals. In their analyses 
of the independent effects of obesity, these investigators found that obesity was 
associated with decrements in visual and verbal memory for both men and women (after 
adjusting for age). However, with the addition of the covariate set (i.e., hypertension, 
diabetes, BMI, total cholesterol, cigarette use, education, occupation, and English as a 
second language), the magnitude of these associations was reduced in men, and no longer 
significant in women.  
Cournot et al. (2006) analyzed the relationship between BMI and cognitive 
functioning in a prospective study that followed 2,223 healthy individuals aged 32 to 62 
years from 1996 to 2001. These investigators observed that BMI at baseline was 
associated with poorer performance on a word-list learning test (an adapted version of the 
Rey Auditory Verbal Learning Test [Rey, 1958]) in a linear fashion. Additionally, higher 
BMI at baseline was associated with significantly higher decline in word-list learning 
over time. The researchers did not observe any associations between change in BMI and 
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memory performance. Gunstad et al. (2006) also analyzed the relationships between 
obesity and performance on a word-list learning task. In their between- subjects analysis, 
they found that obese individuals demonstrated significantly poorer memory performance 
when comparing persons across adult lifespan (21 to 82 years) and in younger and 
middle-aged adults (21 to 50 years). The investigators did not find any interaction 
between BMI and age on the word-list learning test. However, they did not use an 
established measure in their assessment of memory performance, nor did they provide 
reliability and validity statistics for the specific measure that was used. Further, although 
the investigators reported there were no significant between-group differences for age, 
estimated IQ, education, anxiety, and depressive symptoms, they did not control for other 
potential confounding variables (i.e., cardiovascular risk factors, type II diabetes, OSAS) 
in their analyses. Thus, this study had some potentially significant methodological 
problems.  
In a more methodologically sound study, Gunstad et al. (2010) assessed the 
relationships between different obesity indices (i.e., BMI, WHR, waist circumference 
[WC]) and cognitive functioning in 1,703 participants from the Baltimore Longitudinal 
Study of Aging. They used three measures to analyze memory, including the California 
Verbal Learning Test (CVLT; Delis, 1987), Prospective Memory Test, and the Benton 
Visual Retention Test (BVLT; Benton, 1946). In their longitudinal mixed-effects 
regression models with obesity index, age, sex, years of education, hypertension status, 
glucose intolerance or diabetes status, and anti-lipid medication used as covariates, they 
observed that BMI and WHR were related to significantly poorer performance on 
Prospective Memory, and WC and WHR were associated with significantly poorer 
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performance on the BVLT. Additionally, they found a significant interaction between age 
and all of the obesity indices on the BVLT, such that performance decreased over time as 
a function of obesity.  
Unlike the aforementioned studies, Boeka and Lokken (2008) did not observe 
significantly poorer performance on the Logical Memory subtest of the WMS (Wechsler, 
1993) and the California Verbal Learning Test- II (CVLT-II; Delis, 2000) among 
extremely obese individuals (mean BMI = 51.18 kg/m2) compared to normative data. 
Additionally, they used a series of one-way analysis of variance (ANOVA) tests to 
investigate relationships between cognitive performance and associated medical 
problems, including hypertension, type II diabetes, and OSAS. However, they did not 
find any significant differences with and without these self-reported conditions. Although 
these investigators examined differences between groups with co-morbid health 
problems, they did not specifically control for them in their analyses, which could have 
impacted the results. Moreover, the participants’ medical diagnoses were self-reported, 
and not based on their medical records or examinations done by those involved in 
conducting the study.  
Overall, the literature highlights obesity as a risk factor for visual and verbal 
memory deficits. Multiple studies have observed that this relationship is apparent even 
when adjusting for other variables that could impact the association (i.e., hypertension, 
diabetes, age, etc.). Thus, there is evidence to support the notion that obesity is an 
independent risk factor for memory deficits, and there is some evidence to suggest that 
these memory impairments may be more salient in men than women. Further, different 
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obesity indices may moderate the impact of obesity on memory performance, such that 
abdominal obesity magnifies the relationship. 
Dementia and Alzheimer’s Disease. Obesity increases the risk of vascular 
diseases, and there is mounting evidence connecting vascular diseases, such as 
hypertension, coronary heart disease, and diabetes mellitus to the development of 
dementia (Skoog et al., 1996). Considering these associations, several investigators have 
analyzed the relationships between overweight and obesity and the development of 
dementia and Alzheimer’s Disease (AD). Results from these studies suggest that obesity 
is a risk factor for dementia and AD (Gustafson et al., 2004; Kivipelto et al., 2005; Razay 
et al., 2006).  
Beydoun, Beydoun, and Wang (2008) conducted a review of the literature 
pertaining to the relationship between obesity and dementia. Their analysis of 10 studies 
yielded a significant U-shaped association between BMI and dementia, such that the risk 
for dementia increased for obese and underweight persons. They also determined that 
weight gain and high WC, or skin-fold thickness, increased the risk of dementia in the 
studies analyzed. These investigators concluded that there is a moderate relationship 
between obesity and the risks for dementia and AD.  
Several longitudinal studies have investigated the relationship between body 
weight and dementia. Gustafson et al. (2003) conducted an 18-year follow-up study that 
tracked a cohort of 392 Swedish individuals aged 70 to 88 years at baseline. They 
observed that 93 participants developed dementia. Women who developed dementia 
between the ages of 79 and 88 years were overweight, and had higher average BMI at age 
70, 75, and 79 years compared to non-demented women. Moreover, a higher degree of 
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overweight was reported in women who developed AD at 70, 75, and 79 years compared 
to non-demented women. Additionally, for every 1.0 increase in BMI at age 70 years, AD 
risk increased by 36 %. However, these relationships were not observed in men.  
Kivipelto et al. (2005) conducted a study that expanded the findings from 
Gustafson et al. (2003) to a younger population and suggested obesity is a risk factor for 
the development of dementia in both men and women. Kivipelto et al.’s (2005) study 
consisted of analyzing survey data collected from the Cardiovascular Risk Factors, 
Aging, and Dementia (CAIDE) study. Their sample consisted of 1,449 participants aged 
65 to 79 years who participated in follow-up at 21 years, on average. They found that 
obesity at midlife was associated with the risk of dementia and AD. Moreover, they 
reported that when hypertension and high total cholesterol level were added to the model, 
there was a 2-fold increase in the risk of dementia.  
A study conducted by Stewart et al. (2005) suggests the relationship between 
obesity and dementia is also apparent in men. In this 32-year prospective study of 1,890 
Japanese American men from the Honolulu-Asia Aging study, increasing BMI was 
associated with an increased risk for vascular dementia. However, this relationship was 
not true for AD. These investigators also observed that dementia-associated weight loss 
occurs prior to the onset of the disease and increases by the time of diagnosis. Razay et 
al.’s (2006) study examining the relationship between obesity and AD gleaned somewhat 
contradictory results. They found that the prevalence of obesity was significantly higher 
in a group of individuals, including men and women, diagnosed with AD compared to 
normal controls. Moreover, using logistic regression analyses, they observed that obesity 
was associated with an almost 10-fold increase in the risk of AD. They also observed this 
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association in underweight persons, with an 8-fold increase in the risk of AD. This study 
suggests that later-life obesity is associated with the development of AD.    
Taken together, the research analyzing the relationship between obesity and 
dementia suggests that they are correlated. Multiple longitudinal studies have observed 
relationships between obesity and dementia and AD, such that increasing obesity is 
associated with increased risk for dementia and AD. Further, when obesity is combined 
with other risk factors, such as hypertension and high cholesterol, the risk for developing 
AD increases substantially. The literature also suggests that underweight persons may be 
at greater risk for developing dementia and AD than normal weight individuals.  
Neuropathological Mechanisms. Though explanations regarding the underlying 
mechanisms relating to obesity and cognitive dysfunction remain unclear, several 
hypotheses have been posited. First, obesity causes vascular changes that necessitate 
increased blood flow throughout the body and may prevent optimal blood flow to the 
brain (Dagenais et al., 2005; Waldstein et al., 2006). An alternative explanation is that 
obesity can affect glucose tolerance and insulin regulation, and these factors are 
acknowledged to impair cognitive functioning (Convit et al., 2003; Teunissen et al., 
2003). Another perspective is that adipose tissue contains cells that secrete proteins (e.g., 
leptin), and these proteins may negatively impact cognition when existent at high levels 
(Gunstad et al., 2008; Harvey, 2007; Wilson et al., 2002). Finally, research has 
demonstrated associations between BDNF and obesity, as well as memory performance, 
which suggest that BDNF may be involved in the underlying mechanisms linking obesity 
to cognitive dysfunction (Gunstad et al., 2008; Hariri et al., 2003).   
 44 
Several studies have examined the relationship between obesity and structural 
changes in the brain that result from vascular and metabolic processes. These 
investigations provide insight into the underlying mechanisms involved in the 
relationship between obesity and dementia. Convit et al. (2003) found that reduced 
glucose tolerance was associated with hippocampal atrophy and poor memory 
performance in a sample of normal elderly individuals. Additionally, Jugust et al. (2005) 
observed a relationship between obesity and hippocampal atrophy, as well as white-
matter hyperintensities. Gustafson et al. (2004) found relationships between overweight 
and obesity and white matter lesions in elderly women. Finally, Ward et al. (2005) 
observed an association between BMI and decreased global brain volume. Taken 
together, these studies provide evidence for the relationship between obesity and changes 
in brain structure that could affect cognitive functioning. 
Summary 
 Chapter II presented a review of the literature regarding the medical 
complications associated with obesity, including diabetes, hypertension and 
cardiovascular disease, cancer, and OSAS. Additionally, an in-depth review of the 
literature regarding neurocognitive functioning in both obese individuals and those with 
OSAS was presented. Chapter III will outline the methods, which will include a 
discussion of the participants, inclusion and exclusion criteria, procedures, measures, and 
data analyses. 
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Chapter III: Methods 
Participants 
 Three hundred participants were recruited to participate in a randomized clinical 
trial, referred to as Project Breathe (Aloia, 2012). Participants for Project Breathe were 
recruited from the Sleep Center at National Jewish Health (NJH) and were between the 
ages of 30 to 80 years. All participants were diagnosed with mild to severe OSAS and 
had no previous history of CPAP treatment. Of the 300 participants recruited for Project 
Breathe, 102 met the inclusion and exclusion criteria for the present study. Demographic 
characteristics of the final sample are outlined in Chapter IV.  
Inclusion Criteria 
 The inclusion criteria for participants accepted into the Project Breathe were as 
follows: 1) 30 to 80-years-old; 2) diagnoses of OSAS based on initial polysomnography 
(PSG); 3) choice of CPAP as preferred method of treatment; and 4) considered by sleep 
physicians to be responders to CPAP. Participants were considered responders to CPAP 
if their apnea-hypopnea index (AHI) was less than 10, they did not snore, and they had an 
arousal index of less than 10 when titrated with the appropriate CPAP pressure in the 
sleep lab. An additional inclusion criterion was added for the present study: Participants 
who demonstrated adherence to CPAP, defined as an average nightly usage of four or 
more hours over six months of involvement in Project Breathe, were included.   
 
 46 
Exclusion Criteria 
 The exclusion criteria for participants accepted into the Project Breathe were the 
following: 1) AHI < 15 on the PSG and no daytime functional symptoms or associated 
cardiovascular disease; 2) PSG confirmation of no OSA diagnosis; 3) diagnosis of a sleep 
disorder other than OSA that causes arousals form sleep; 4) past treatment of OSAS; 5) 
current substance abuse; 6) diagnosis of a serious medical condition; 7) significant global 
cognitive impairment on a brief screening (MMSE < 26/30); 8) history of or current 
diagnosis of a neurological illness; 9) history of or current diagnosis of a major 
psychiatric illness, except depression; 10) change in anti-depressant medications over the 
past three months.  
Procedure 
 The Institutional Review Board at NJH approved Project Breathe. Project Breathe 
aimed to compare the efficacy of brief behavioral approaches to CPAP treatment on 
adherence and clinical outcomes. Further details regarding the behavioral interventions 
and their impact on CPAP adherence will be reported elsewhere as this information is not 
pertinent to the proposed study.  
 Research assistants at NJH recruited all study participants. Participants who 
agreed to be contacted regarding research studies, and who met the inclusion and 
exclusion criteria (determined by a sleep technician during his/her overnight sleep study 
at the Sleep Center at NJH), were phoned. They were told that the study was designed to 
identify methods to improve the response to CPAP treatment and that their use of CPAP 
would be monitored throughout their involvement in the study. Once participants were 
recruited, they were scheduled for a baseline assessment at NJH. Research assistants 
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coordinated with participants’ physician and home healthcare company to secure a CPAP 
device for the participant. The research assistants programmed the CPAP machine with 
the participants’ prescribed pressure, and handed off the CPAP to the patient at the 
baseline visit. Immediately following the baseline visit participants met with a 
representative at the home healthcare company who conducted a mask fitting and 
educated the patient on how to use the CPAP machine.     
 All participants received an Informed Consent Document, which introduced the 
purpose of the study, plan, and procedures. Research assistants provided participants with 
further details and clarification as needed, and made sure they understood the information 
entirely before signing the document. Participants were given a signed copy of the 
Informed Consent Document. After signing the document, participants completed the 
MMSE and the Alcohol Use Disorders Identification Test (AUDIT) to further determine 
their eligibility to participate in the study. Participants who scored less than 26 out of 30 
on the MMSE and/or greater than or equal to 8 on the AUDIT were informed that they 
would not be able to participate, and they were paid $25.00 for their time.  
 Participants completed baseline assessments, which included measures of 
cognitive functioning, mood, daytime sleepiness, sleep-related functional outcomes, and 
psychological constructs of behavior change principles. These assessments were repeated 
at 3, 6, and 12-month follow-up visits after the initiation of treatment. Participants were 
paid $50.00 for each follow-up visit. Data from baseline, 3, and 6-month follow-ups were 
used in the present study.  
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Measures 
 A variety of reliable and valid measures were used in Project Breathe to assess 
cognitive functioning, mood, daytime sleepiness, sleep-related functional outcomes, and 
psychological constructs of behavior change principles. Those of interest in the present 
study were primarily related to neurocognitive functioning, but also included measures of 
anxiety and depressive symptoms as their presence can influence cognitive outcomes. All 
measures analyzed in the present study are described in detail below.  
 Demographics. Participants were asked to report their height, weight, age, sex, 
level of education (in years), ethnicity, employment status and household income, marital 
status, and whether or not they had any chronic health conditions (e.g., diabetes, 
hypertension). Participants’ BMI and level of OSAS severity were obtained from the 
PSG report.  
 American National Adult Reading Test (AMNART; Grober, Sliwinski, & 
Korey 1991). The AMNART was intended to be used as a covariate in the present study. 
The AMNART is the American version of the Nelson Adult Reading Test (NART), 
which was developed in England by Nelson (1982) to approximate premorbid IQ in 
patients with dementia. The NART requires the reading of irregular words that cannot be 
pronounced correctly with the typical rules used to navigate spelling and sound (Grober, 
Sliwinski, & Korey, 1991). These irregular words are used in an effort to amplify the 
importance of previous familiarity with the words, and to decrease dependence on present 
ability to use rules to map spelling and sound. IQ estimates based on the reading of 
irregular words from the NART have been found to be better indicators of premorbid IQ 
in patients with dementia than estimates based on reading regular words (Nelson & 
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O’Connell, 1978). The British version includes words and spellings that might be 
unrecognizable to American English speakers; thus, Schwartz and Saffran (1987; cited in 
Grober, Sliwinski, & Korey, 1991) developed the American version.  
The AMNART was standardized on 109 normal adults ages 40 to 89 years. 
Schwartz and Saffran (1987; cited in Grober, Sliwinski, & Korey, 1991) demonstrated 
that predicted IQ from the AMNART highly correlated with WAIS IQ measures when 
controlling for the impact of education: r = .72 for the Verbal Intelligence Quotient, r = 
.51 for the Performance Intelligence Quotient, and r = .72 for the FSIQ. These 
investigators also found that the predicted IQ of patients with AD was no different than 
the scores of normal controls; whereas, the current IQ of the patients with AD was 
consistently lower. In similar analyses, Grober and Sliwinski (1991) found that estimated 
premorbid IQ exceeded current IQ by at least 10 points in patients with dementia, but did 
not differ for non-demented participants. As the AMNART is a measure of premorbid IQ, 
these results highlight its construct validity: It would be expected that persons with 
dementia would perform poorer on a measure of current IQ (i.e., the WAIS) than a 
measure that assesses their IQ prior to the onset of dementia. The AMNART would not 
provide an accurate estimate of current intellectual functioning in individuals with 
dementia; however, its use as an estimate of current IQ in the present study is appropriate 
as participants were screened for, and excluded, if they met criteria for global cognitive 
impairment.  
 Hopkins Verbal Learning Test Revised (HVLT-R; Brandt & Benedict, 2001). 
The HVLT-R is a brief test of verbal learning and memory. The HVLT-R is a revised 
version of the HVLT, which was published by Brandt in 1991. The measure was 
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designed for use with moderately demented patients, particularly in situations that call for 
repeated neuropsychological evaluations. The measure is comprised of 12-item word 
lists, which consist of nouns that represent three semantic categories (e.g., musical 
instruments, spices, four-legged animals). It includes three learning trials, a delayed recall 
trial, and a yes/no delayed recognition trial.   
 The administration of the HVLT-R involves the examiner reading the word list 
aloud and asking the patient to verbally repeat the list of words in any order. The 
examiner reads the list of words three times, and the patient completes three free recall 
trials. The examiner records recall performance verbatim after each immediate recall. 
After a 20 to 25 minute delay, the patient completes one more free recall and a delayed 
recognition trial. For the recognition trial the participant is asked to identify target words 
by saying “yes” and non-target words by saying “no.”  
 The HVLT-R is scored by calculating the sum of correct free recall responses. 
Minor pronunciation mistakes are counted as correct and added to the total for each recall 
trial. In addition to the recall totals, including the delayed recall, three additional 
measures of learning and memory can be calculated. These consist of the Total Recall 
score (i.e., sum of learning trials 1 to 3), the Percent Retained after the delay (i.e., trial 4 
recall divided by the best of trials 2 and 3 [x 100]), and the Recognition Discrimination 
index (i.e., the number of true positives less the number of false positives). Raw scores 
are converted to T scores according to age-based tables.  
 The normative sample for the HVLT-R consisted of 1179 individuals who denied 
having neurological or psychiatric disorders (Brandt & Benedict, 2001). The mean age of 
the sample was 59 years (SD = 18.62), and ages ranged from 16 to 92 years. The sample 
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had 2 to 20 years of education, with a mean of 13.47 (SD = 2.88). The race and ethnicity 
of participants was not reported. The authors noted that the distributions for most age 
groups of the four primary scores (i.e., Total Recall, Delayed Recall, Percent Retention, 
and Recognition Discrimination Index) were all restricted in range, or significantly 
skewed. Additionally, there were ceiling effects for some variables, particularly for 
younger age groups. 
 In an assessment of 40 older adults who completed different forms of the test with 
an average time between tests of 6 weeks, Benedict et al. (1998) reported the following 
coefficients for the main HVLT-R variables: .74 for Total Recall; .66 for Delayed Recall; 
.39 for Percent Retention; and .40 for the Recognition Discrimination Index. The six 
alternate forms have demonstrated reliability for the recall trials (Benedict et al., 1998); 
however, they have shown differences in the false-positive responses on the Delayed 
Recognition trial. Specifically, Forms 1, 2, and 4 were more difficult on the Delayed 
Recognition trial than the other Forms. Due to these differences, Benedict et al. (1998) 
published adjusted norms for the Delayed Recognition trial between forms 1, 2, and 4 and 
forms 3, 5, and 6. Practice effects have been shown to be minimal: less than 1 point in 
Total Recall on the second testing (Barr, 2003).  
 The HVLT-R has demonstrated convergent validity with a similar measure (i.e., 
CVLT) in a sample of patients with AD (Lacritz, Cullum, & Weiner, 2001). 
Administration of the first test was performed in the morning and the second in the 
afternoon for each participant. The investigators found that Total Learning (r = .36), 
Delayed Recall (r = .62), Intrusion Errors (r = .34), and Recognition Hits (r = .48) were 
moderately correlated between tests. Several researchers have reported that the HVLT-R 
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is useful in screening for dementia (Hogervorst et al., 2002; Shapiro et al., 1999), and 
Carey et al. (2004) reported that the HVLT-R is effective in detecting neuropsychological 
deficits in individuals who have been diagnosed with HIV.  
Paced Auditory Serial Addition Test (PASAT; Gronwell, 1977). The PASAT is 
a serial addition task used to measure working memory, divided attention, and 
information processing speed (Strauss et al., 2006). There are several different versions 
of the test available; the version used in this study is the auditory computerized version 
(Wingenfeld et al., 1999), which consists of four 50-item trials. The PASAT is 
appropriate to use with a wide range of ages, with norms available for ages 16 to 17 years 
depending on the version.  
The test consists of a random auditory presentation of numbers from 1 to 9. The 
examinee is instructed to add pairs of consecutive numbers, such that each new number is 
added to the number that immediately preceded it. For instance, if the stimulus “2” 
followed by “9” is stated, the examinee would respond “11,” and if the next stimulus is 
“3,” the examinee would respond “14.” This pattern continues until the end of the trial, 
which consists of 50 numbers. The speed of the presented stimuli incrementally increases 
with each set of numbers; thus, decreasing the available response time for each trial.  
The PASAT necessitates that the examinee maintains attention, uses working 
memory by performing mental calculations, and does this at an increasingly faster pace. 
It is considered a strong measure of divided attention, sustained attention, and working 
memory (Strauss et al., 2006). The PASAT has demonstrated very high internal 
consistency in adults (r = .90), and it has excellent test-retest reliability (r > .90) with 
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short retest intervals (i.e., 7 to 10 days; McCaffrey et al., 1995) and moderate test-retest 
reliabilities (r = .73) with longer intervals (Schachinger et al., 2003).  
The PASAT demonstrates significant practice effects, regardless of the interval 
between tests. Reports of up to an 18 % increase in scores between first and second tests 
have been reported (Stuss et al., 1989). However, after the second presentation, practice 
effects appear to dissipate (Gronwall, 1977). The PASAT is moderately correlated with 
other measures of attention (O’Donnell et al., 1994) and IQ (Crawford et al., 1998), and 
highly correlated with tests of mathematical abilities (Crawford et al., 1998). The 
advantages associated with mathematic aptitude are likely related to reaction time, as 
individuals with stronger arithmetic skills are able to respond faster, thereby increasing 
the time interval between items, which allows them to rehearse the previous item 
(Chronicle & MacGregor, 1998). However, individuals with weaker mathematical skills 
take longer to respond, and thus, decrease their opportunity to rehearse the previous item 
(Chronicle & MacGregor, 1998).   
Psychomotor Vigilance Task (PVT; Dinges & Powell, 1985). The PVT 
measures sustained attention and the ability to respond to stimuli in a timely manner. The 
PVT requires the subject to respond to a small red light stimulus by pressing the response 
button as soon as the stimulus appears. When the subject presses the response button, the 
stimulus displays the response time in milliseconds. The subject is instructed to press the 
button as soon as the stimulus appears, to keep their response time as low as possible, and 
not to press the button too soon. When the response button is pressed prematurely, the 
devise shows a false start (FS) warning. (Dorian, Rogers, & Dinges, 2005).  
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The PVT has very minor learning effects (Dorian et al., 2005). Researchers have 
demonstrated that the sensitivity of the PVT is enhanced by using longer task durations 
(e.g., 20 minutes; Dinges & Weaver, 2003). As such, the task duration used in the present 
study was 20 minutes. Many studies have found that the PVT is a valid assessment of the 
neurocognitive effects of sleep loss on wakefulness as demonstrated in sustained 
attention, and this measure is commonly used in research related to the cognitive 
consequences of OSAS (Dorian et al., 2005).  
Trail Making Test (TMT; Reitan, 1992). The TMT consists of two parts, A and 
B, which cumulatively test attention, speed, and mental flexibility. The TMT A entails 
connecting 25 encircled numbers in consecutive order that are randomly scattered on the 
page. The TMT B is similar; however, it also has encircled letters, and the examinee is 
required to alternate between numbers and letters in the proper order. Whereas the TMT 
A assesses attention, the TMT B is commonly used as a test of cognitive flexibility, as it 
requires divided attention and alternating sequencing (Strauss et al., 2006). The standard 
administration procedure involves practice trials for both parts A and B, and the entire 
test takes about 5 to 10 minutes to administer. Scoring is based on the time in seconds 
required to complete the task.  
The TMT is appropriate to use with individuals ages 15 to 89 years. Performance 
on the TMT is impacted by age, with decreasing scores as age increases. However, these 
age-related differences are related to speed, as opposed to accuracy (Backman et al., 
2004). Additionally, lower levels of education and lower IQ are associated with poorer 
performance on the TMT, with lower IQ being more strongly related to decreased 
performance (Steinberg et al., 2005).  
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The TMT has demonstrated adequate test-retest reliability for Part A (r = .79) and 
high test-retest reliability for Part B (r = .89) in a large sample of individuals aged 15 to 
83 years (Dikmen et al., 1999). Practice effects are associated with short intervals 
between tests (Bornstein, Baker, & Douglas, 1987), but over longer intervals (4 to 24 
months) practice effects diminish (Levine et al., 2004). The TMT B correlates moderately 
well with scores on other tests of processing speed (Royan et al., 2004) and cognitive 
flexibility (Kortte, Horner, & Windham, 2002).   
Adherence. Adherence to CPAP was measured using electronic monitoring 
equipment. Participants received either a modem that attached directly to their CPAP 
device and automatically downloaded their usage data, or a microchip that could be 
removed, and the data were manually downloaded at follow-up visits. Adherence was 
measured as the amount of time the CPAP device was turned on and the amount of time 
the mask was properly positioned on the face and maintaining the appropriate prescribed 
pressure.  
Beck Depression Inventory-II (BDI-II; Beck, Steer, & Brown, 1996). The BDI-
II is a 21-item self-report measure of depressive symptoms. The BDI-II reflects the 
diagnostic criteria for Major Depressive Disorder outlined in the Diagnostic and 
Statistical manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR; 
American Psychiatric Association, 2000). The BDI-II was adapted from an earlier 
version of the instrument and is one of the most widely used instruments for assessing the 
severity of depressive symptoms (Steer et al., 1999), which include the following: 
sadness, pessimism, past failure, loss of pleasure, guilty feelings, punishment feelings, 
self-dislike, self-criticalness, suicidal thoughts, crying, agitation, loss of interest, 
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indecisiveness, worthlessness, loss of energy, changes in sleeping, irritability, changes in 
appetite, concentration difficulty, tiredness or fatigue, and loss of interest in sex. Each 
item has a list of four statements that are organized in increasing severity regarding a 
particular symptom of depression, and participants choose one statement that matches 
their experience in the past two weeks. The BDI-II is appropriate to use with individuals 
ages 13 to 80 years.   
The BDI-II has demonstrated very high internal consistency, with a Cronbach’s 
alpha of .92 for clinical patients and .93 for non-clinical patients. The test-retest 
reliability with a one-week interval between tests was .93 in a sample of outpatients. 
Additionally, the BDI-II is highly correlated with its previous version (r = .93; Arnau et 
al., 2001). 
 Hospital Anxiety and Depression Scale (HADS; Zigmond & Snaith, 1983). The 
HADS is a self-report measure that consists of anxiety and depression subscales, each of 
which contain seven items. The HADS was developed to identify anxiety and depression 
in general medical outpatient populations. The items comprising the HADS were selected 
to recognize anxiety and depression independent of somatic symptoms, as these are 
common in patient populations. 
 The HADS demonstrates good internal consistency, with Cronbach’s alpha values 
of .83 and .74 for the anxiety and depression subscales, respectively (Pallant & Bailey, 
2005). In an investigation of the HADS, Bjelland et al. (2002) found that the mean 
correlation coefficient between the anxiety and depression subscales was .56, which is 
quite high, and brings into question the dimensionality of the scale. Despite the high 
correlations between the subscales, the HADS has demonstrated high sensitivity and 
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adequate specificity in identifying anxiety and depression in patient populations (Pallant 
& Bailey, 2005).  
Data Analysis 
 Prior to conducting the primary data analysis, participants were categorized as 
obese or non-obese according to the guidelines established by the WHO (1998), such that 
those with a BMI of less than 30 kg/m2 were considered non-obese, and those with a BMI 
greater than or equal to 30 kg/m2 were considered obese. Preliminary analyses were 
conducted to define the demographic characteristics of the sample, including age, sex, 
level of education (in years), ethnicity, employment status, household income, marital 
status, and the presence of chronic health conditions (e.g., diabetes, hypertension). 
Preliminary analyses were also performed to determine if differences in these 
demographic variables, as well as AMNART, BDI-II and HADS scores existed between 
obese and non-obese participants. Independent samples t-tests were used to analyze these 
differences.  
 Due to correlations among dependent variables in the present study, analyses were 
conducted using univariate, as opposed to multivariate methods. Though the disadvantage 
of this approach includes an inflation of Type I error, the correlations among dependent 
variables would significantly reduce statistical power in a multivariate design 
(Tabachnick & Fidell, 2007). Thus, analysis of covariance (ANCOVA) and repeated 
measures analysis of covariance (RM-ANCOVA) were the primary methods used for 
testing the hypotheses of the present study. ANCOVA is an extension of analysis of 
variance (ANOVA) in which main effects are interpreted after adjusting for one or more 
covariates. ANCOVA is commonly used to increase the sensitivity of the test of main 
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effects by accounting for the relationship between the dependent variable and covariate(s) 
(Tabachnick & Fidell, 2007). RM-ANCOVA is used for longitudinal studies in which the 
researcher is interested in the effects of treatment over time; both within-subjects and 
between-subjects differences can be analyzed (Dimitrov, 2009).     
 The ANCOVA assumptions were tested prior to conducting the analyses. These 
assumptions included the following: 1) normality of sampling distributions, 2) 
homogeneity of variance, 3) linearity, and 4) homogeneity of regression slopes. RM-
ANCOVA has the additional assumption of sphericity, which was also tested prior to 
conducting the analyses.  
Summary 
 Chapter III provided a description of the methodology used in the present study. 
Descriptions of the participants, inclusion and exclusion criteria, procedures, and 
measures were included. The preliminary and primary analyses that were used to test the 
hypotheses of this study were also discussed. Chapter IV includes the results of both the 
preliminary and primary data analyses.   
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Chapter IV: Results 
 Chapter IV will highlight the data screening methods used in the present study, 
including an analysis of missing data, and the process by which theoretically derived 
covariates were selected for the final models. This chapter will also summarize the 
methods used to check assumptions of ANCOVA and RM-ANCOVA and the results of 
these analyses. Finally, results of the preliminary and primary data analyses will be 
reported.  
Data Screening 
 Missing Data. Missing data is a common problem in longitudinal data analysis; 
however, the pattern of missing data is more important than the quantity. Missing data are 
generally categorized according to the following characteristics: missing completely at 
random (MCAR), missing at random or ignorable non-response (MAR), and missing not 
at random or non-ignorable response (MNAR). The best scenario occurs when missing 
values are MCAR as this indicates that the pattern of missingness is unpredictable and 
not related to the independent or dependent variables. When variables are MAR, the 
pattern of missing values is predictable based on other variables, and in the case of 
MNAR, the missing values are related to the dependent variable (Tabachnick & Fidell, 
2007).  
 The pattern of missing data was analyzed using the Missing Values Analysis 
(MVA) in SPSS 19.0. The following variables were selected for the MVA for baseline, 3, 
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and 6-month follow-up visits: PVT scores; HVLT Total Recall and Delayed Recall 
scores; TMT A scores; TMT B scores; and PASAT Total scores. The percentages of 
missing data for these variables across time points are displayed in Table 1. There were 
no missing values for the demographic variables of interest in this study; thus, these 
variables were not included in the MVA.  
Table 1 
 
Missing Data Percentages at Baseline, Three, and Six Month Follow-Ups 
Variable Time Point Percentage 
PVT Baseline 13.9 % 
PVT 3-month 9.6 % 
PVT 6-month 16.5 % 
HVLT Trial 1, 2, 3, and 
Delayed Baseline .9 % 
HVLT Trial 1, 2, 3, and 
Delayed 3-month 1.7 % 
HVLT Trial 1, 2, 3, and 
Delayed 6-month 10.4 % 
TMT A and B Baseline 0 % 
TMT A and B 3-month 1.7 % 
TMT A and B 6-month 10.4 % 
PASAT Trials 1, 2, 3, and 
4 Baseline .9 % 
PASAT Trials 1, 2, 3, and 
4 3-month 1.7 % 
PASAT Trials 1, 2, 3, and 
4 6-month 10.4 % 
 
 Little’s MCAR test demonstrated that missing values for all outcome variables 
were missing in a completely random pattern. Results from Little’s MCAR test are 
outlined in Table 2. 
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Table 2 
 
Results of Little’s MCAR Test 
Variable df χ2 p value 
PVT 9 14.908 .086 
HVLT Total Recall 15 11.096 .746 
HVLT Delayed Recall 5 3.658 .600 
TMT A 3 3.048 .384 
TMT B 3 .766 .858 
PASAT Total 20 11.482 .933 
   
 Tabachnick and Fidell (2007) explained that a small number of data (i.e., 5 % or 
less) missing in a random pattern from a large dataset (i.e., N > 100) typically causes less 
serious problems, and virtually any method used for dealing with missing data yields 
similar results. Though values were missing at a higher rate than 5 % for the PVT and 
other variables at the third time point, the data were MCAR. The simplest and most 
pragmatic way of imputing missing values is through Expectation Maximization (EM); 
this approach is appropriate to use when missing values are MCAR. EM is an iterative 
procedure that involves using non-missing variables to impute missing values, and then 
checks to determine whether that value is the most likely. If the imputed value is not the 
most likely, a more likely value is re-imputed, and this process occurs until the most 
likely value is reached. This simple imputation technique can result in underestimated 
standard deviation and standard error due to the decrease in variation; thus, inferential 
results must be interpreted with caution (Tabachnick & Fidell, 2007).  
Selection of Covariates 
 Based on the literature review, a large number of variables could impact 
participants’ neuropsychological performance. Ideally, each of these potential sources of 
variability could have been adjusted for in the analyses; however, there are a number of 
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assumptions surrounding covariates that need to be assessed before including them in the 
models. First, covariates should be correlated with the dependent variable, but 
uncorrelated with each other. Second, the relationship between the covariate and the 
dependent variable should be the same for all combinations of factors; this assumption is 
referred to as homogeneity of regression slopes. Covariates need to be selected carefully, 
as including extraneous covariates can complicate the models and result in reduced 
statistical power (Tabachnick & Fidell, 2007).  
 The initial set of covariates was theoretically based and included the following 
variables: sex, age, baseline BDI score, presence of hypertension, and presence of 
diabetes. Statistically significant, though weak, negative correlations were observed 
between age and baseline BDI score r (100) = -.213, p = .032, as well as years of 
education and baseline BDI score r (100) = -.264, p = .007. Given the correlations 
between these variables, their correlations with the dependent variables were analyzed, 
and the variables most strongly correlated with the outcome variables were selected for 
inclusion in the models, as recommended by Tabachnick and Fidell (2007). Age and 
years of education demonstrated statistically significant correlations with dependent 
variables, whereas baseline BDI score did not. Based on this analysis, baseline BDI score 
was eliminated from the covariate set.  
 After analyzing correlations among covariates, as well as covariates and 
dependent variables, the remaining covariates (i.e., sex, age, years of education, presence 
of hypertension, and presence of diabetes) were further tested for the assumption of 
homogeneity of regression slopes to determine whether or not they were appropriate to 
include in the models. This assumption was tested using SPSS 19.0 by analyzing 
 63 
interactions between the covariates and the independent variable (i.e., BMI: obese vs. 
non-obese). Sex demonstrated a statistically significant interaction with the independent 
variable F (1, 98) = 6.054, p < .05, ηp2 = .058. Presence of diabetes also demonstrated a 
statistically significant interaction with the independent variable F (1, 98) = 4.064, p < 
.05, ηp2 = .040. Thus, the null hypothesis of homogeneity of regression slopes was 
rejected and these were not appropriate covariates to include in the analyses. After 
evaluating the potential covariates, the following covariate set was appropriate to include 
in the analyses: age, years of education, and presence of hypertension.  
 Once age, years of education, and presence of hypertension were identified as 
appropriate covariates, it was necessary to test them for the additional assumption of 
linearity. ANCOVA is based on the assumption that there is a linear relationship between 
covariates and the dependent variables, and violations of this assumption reduce the 
power of the statistical test (Tabachnick & Fidell, 2007). This assumption was assessed 
using the test of linearity within the compare means function in SPSS 19.0. Age 
demonstrated a linear relationship with all outcome variables that were statistically 
significant at the p < .01 level. However, years of education and baseline HADS score did 
not demonstrate linear relationships with outcome variables. Tabachnick and Fidell 
(2007) noted that if covariates do not demonstrate linear relationships, the researcher 
could consider transforming the variables or removing them from the model. Given the 
difficulties associated with interpreting transformed variables, these covariates were 
removed from the models. Based on a thorough analysis of all potential covariates, age 
and presence of hypertension were determined to be appropriate for inclusion in the 
analyses.  
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Assumption Checking for ANCOVA  
 In addition to the homogeneity of regression slopes and linearity assumptions 
previously discussed, several other assumptions needed to be checked prior to conducting 
the ANCOVA, including the assumptions of normality, homogeneity of variance, and 
linearity (Tabachnick & Fidell, 2007).   
 Normality. According to Tabachnick and Fidell (2007), assessing continuous 
variables for normality is an important aspect of screening data for inferential goals. This 
is also an assumption of ANCOVA and RM-ANCOVA; thus, normality of continuous 
dependent variables and covariates was assessed by BMI group. Variables and covariates 
that were screened for normality included age, PVT scores, HVLT Total Recall and 
Delayed Recall scores, TMT A score, TMT B score, and PASAT Total score. Tabachnick 
and Fidell (2007) recommend assessing normality for large sample sizes by analyzing 
skewness and kurtosis, as well as visually appraising the distributions. All variables were 
normally distributed with the exception of those outlined in Table 3.  
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Table 3 
 
Normality of Continuous Dependent Variables and Covariates 
Group Variable Time Point Skewness Kurtosis 
Obese HVLT Delayed 
Recall 6-month -.1667 3.098 
Non-Obese HVLT Delayed 
Recall 6-month -.1913 3.098 
Obese TMT A 3-month 1.278 3.408 
Obese TMT A 6-month 1.527 2.572 
Non-Obese TMT A Baseline 1.059 1.227 
Non-Obese TMT A 3-month 1.508 2.775 
Obese PASAT Baseline -1.292 1.331 
Obese PASAT 3-month -1.270 1.284 
Obese PASAT 6-month -1.424 1.271 
Non-Obese PASAT 3-month -1.189 .951 
Non-Obese PASAT 6-month -1.181 .642 
 
The kurtotic distribution of the HVLT Delayed Recall variable was somewhat 
expected as the maximum score is only 12. The negative skewness of this variable 
demonstrates that the majority of participants tended to get upwards of 10 points on the 
Delayed Recall Trial. The same is true of the PASAT Total score, with the majority of 
participants in both groups earning between 150 to 200 points out of a possible 200 
points. The positively skewed and kurtotic distributions of the TMT A scores in the obese 
and non-obese groups again demonstrates that the majority of participants tended to take 
between 20 to 40 seconds to complete the task, with fewer participants exceeding that 
amount of time. Though some variables demonstrated deviations of normality, Dimitrov 
(2010) noted that ANCOVA is generally robust to violations of the assumption of 
normality.      
 Homogeneity of Variance. ANCOVA assumes that the variance of dependent 
variable values within each cell of the design provides a separate estimate of the same 
population variance. The homogeneity of variance assumption was tested in SPSS 19.0 
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using Levene’s Test of Equality of Error Variances. This assumption was tested and met 
for both the ANCOVA and RM-ANCOVA designs as indicated by p values greater than 
.05. Tables 4 and 5 provide results for this test for both the ANCOVA and RM-
ANCOVA.  
Table 4 
 
Levene’s Test of Equality of Error Variances for ANCOVA 
 
Dependent Variable F p value 
PVT 1.097 .354 
HVLT Total Recall .522 .668 
HVLT Delayed Recall .370 .775 
TMT A 1.937 .129 
TMT B 1.204 .312 
PASAT Total 1.800 .152 
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Table 5 
 
Levene’s Test of Equality of Error Variances for RM-ANCOVA 
Dependent 
Variable Time Point F p value 
PVT Baseline 1.097 .354 
PVT 3-month .616 .606 
PVT 6-month .511 .675 
HVLT Total 
Recall Baseline .017 .997 
HVLT Total 
Recall 3-month .970 .413 
HVLT Total 
Recall 6-month .115 .951 
HVLT Delayed 
Recall Baseline .370 .775 
HVLT Delayed 
Recall 3-month 2.399 .072 
HVLT Delayed 
Recall 6-month .188 .905 
TMT A Baseline 1.937 .129 
TMT A 3-month 2.399 .388 
TMT A 6-month .188 .195 
TMT B Baseline 1.204 .312 
TMT B 3-month 1.717 .168 
TMT B 6-month .741 .530 
PASAT Baseline 1.800 .152 
PASAT 3-month .931 .429 
PASAT 6-month .792 .501 
 
Assumption Checking for Repeated Measures ANCOVA  
By checking the data for the assumptions of ANCOVA, the majority of the 
assumptions for RM-ANCOVA were also assessed. However, RM-ANCOVA carries the 
additional assumption of sphericity. When the assumption of sphericity is met, population 
variances of the differences for all levels of the repeated-measures factor are equal 
(Dimitrov, 2010). Sphericity was assessed in SPSS 19.0 using Mauchly’s Test of 
Sphericity. This assumption is met when the p value of Mauchly’s Test of Sphericity is 
greater than .05. Results from this test are outlined in Table 6.  
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Table 6 
 
Mauchly’s Test of Sphericity 
Dependent 
Variable df χ
2 p value 
PVT 2 2.736 .255 
HVLT Total 
Recall 2 7.334 .026 
HVLT Delayed 
Recall 2 8.971 .011 
TMT A 2 .800 .670 
TMT B 2 12.061 .002 
PASAT 2 48.375 .000 
       
 Results from Mauchly’s Test of Sphericity indicate that the following dependent 
variables did not meet the assumption: HVLT Total Recall, HVLT Delayed Recall, TMT 
B, and PASAT. SPSS 19.0 provides corrected F ratios (i.e., Greenhouse-Geisser, Huynh-
Feldt, and Lower Bound) for interpretation when the assumption of sphericity is violated. 
Thus, the corrected F ratios were interpreted in cases of this assumption not being met. 
Girden (1992) recommended using the Greenhouse-Geisser estimate when epsilon 
(provided by SPSS 19.0) is less than .75 and the Huynh-Feldt estimate when epsilon is 
greater than .75. Based on epsilon values, the Greenhouse-Geisser F ratio was interpreted 
for the following variables: HVLT Total Recall, HVLT Delayed Recall, and TMT B. The 
Huynh-Feldt F ratio was interpreted for the PASAT.  
Preliminary Analyses 
 Demographic Characteristics of the Sample. Among the 300 participants 
recruited for Project Breathe, 102 met the inclusion and exclusion criteria for the present 
study. Participants were 66 men and 36 women. The ethnic breakdown of the sample was 
as follows: 77 % white,   9 % black or African American, 3 % American Indian, 3 % 
Asian, 1 % Native Hawaiian, and 7 % identified as “Other.” Ten percent of the sample 
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identified as Hispanic or Latino, and 90 % of the sample identified as not Hispanic nor 
Latino. The average BMI of the sample was 32.35 (SD = 6.86). The age range of the 
sample was 30 to 76 years, and the average age of participants was 54 years (SD = 
11.20).  Among participants, 1 % were underweight, 9 % normal weight, 33 % 
overweight, 44 % obese, and 13 % morbidly obese. On average, the sample completed 16 
years of education (SD = 2.84). Twelve percent of the sample reported a diagnosis of type 
2 diabetes, and 42 % reported having hypertension. Participants used their CPAP device 
for the duration of the six-month study for an average of 6.3 hours each night (SD = 
1.28). Household income, employment status, and marital status frequencies are outlined 
in Table 7.  
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Table 7 
 
Frequencies for Income, Employment Status, and Marital Status Among the 
Sample 
Variable Descriptor Frequency 
Household Income < $10,000 3 % 
 $10,000-14,000 3% 
 $15,000-24,999 4 % 
 $25,000-34,999 4 % 
 $35,000-49,000 12 % 
 $50,000-74,000 15% 
 $75,000-99,999 20% 
 $100,000 or more 39 % 
Employment Status Working Full-Time 69 % 
 Working Part-Time 7 % 
 Unemployed – Looking 1 % 
 Unemployed – Not 
Looking 1 % 
 Homemaker 3 % 
 Student 0 % 
 Disabled 3 % 
 Retired 14 % 
 Other 2 % 
Marital Status Never Married 7 % 
 Living with Partner 3 % 
 Married 70 % 
 Separated or Divorced 16 % 
 Widowed 4 % 
 
 Psychosocial Differences Between Obese and Non-Obese Participants. 
Preliminary analyses were conducted to determine if obese and non-obese participants 
differed on key psychosocial variables, including years of education, estimated 
intelligence (AMNART score), level of depressive symptoms (BDI-II score), and level of 
anxiety symptoms (HADS score). A series of independent samples t-tests were performed 
to identify any group differences in these domains. Given the number of independent 
samples t-tests being performed, the Bonferroni correction, expressed as α′ = α / k, was 
used to minimize the likelihood of making a Type I error (Tabachnick & Fidell, 2007). 
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Therefore, the alpha level used to determine whether or not the independent samples t-
tests were significant was p < .01. Table 8 provides a descriptive summary of the 
aforementioned variables by BMI group. A chi-square test was used to determine if there 
were significant differences in sex between BMI groups. The percentage of males and 
females did not differ by BMI group, χ2 (1, N = 102) = .409, p > .05.  
Table 8 
 
Descriptive Statistics for Psychosocial Variables by BMI Group 
 
Variable 
 
Group 
 
Mean Score 
Standard 
Deviation 
 
Sample Size 
Age Non-Obese 57.86 9.70 44 
 Obese 51.81 11.62 58 
Years of 
Education Non-Obese 16.45 2.96 44 
 Obese 15.02 2.59 58 
AMNART Non-Obese 33.70 10.829 44 
 Obese 34.47 9.829 58 
BDI-II Non-Obese 10.45 8.30 44 
 Obese 12.93 10.71 58 
HADS Non-Obese 20.37 3.03 44 
 Obese 20.28 3.28 58 
    
 Results of the independent samples t-tests are outlined in Table 9. These results 
indicate that there was a statistically significant difference between obese (M = 51.81, SD 
= 11.62) and non-obese (M = 57.86, SD = 9.70) participants in age, t (100) = 2.794, p < 
.01, such that participants in the obese group were younger than those in the non-obese 
group. There were no statistically significant differences between BMI groups in years of 
education, AMNART, BDI-II, or HADS scores. 
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Table 9 
 
Results for Independent Samples T-Tests Assessing Differences Between 
Groups on Psychosocial Variables 
Variable df t p value 
Age 100 2.794 .005 
Years of Education 100 2.608 .011 
AMNART 100 -.372 .711 
BDI-II 100 -1.271 .207 
HADS 100 .141 .888 
 
Results for Specific Hypotheses  
Hypothesis I. Prior to running the ANCOVA, analyses were conducted to 
determine if differences in PVT and TMT A scores at baseline existed between obese and 
non-obese participants without adjusting for age and hypertension. Results of the 
preliminary ANOVA indicate that there was not a statistically significant main effect of 
BMI on PVT scores F (1, 100) = .527, p > .05, ηp2 = .005. Further, there was not a 
statistically significant main effect of BMI on TMT A scores F (1, 100) = .001, p > .05, 
ηp
2 = .000. 
ANCOVA’s were performed to determine if differences existed between obese 
and non-obese participants on baseline PVT and TMT A scores. The independent 
variable was BMI (obese and non-obese), and the covariates were age and hypertension. 
Table 9 provides a descriptive summary of PVT and TMT A scores among BMI groups. 
After adjustment for covariates, no statistically significant main effect of BMI was found 
F (1, 98) = 2.569, p = >.05, ηp2 = .026. An additional ANCOVA with the same 
independent variable and covariates was performed to determine if differences existed 
between obese and non-obese participants on baseline TMT A scores. Table 10 provides 
a descriptive summary of TMT A scores among BMI groups. After adjustment for 
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covariates, no statistically significant main effect of BMI was found F (1, 98) = 1.061, p 
> .05, ηp2 = .011.    
Table 10 
 
Descriptive Statistics for PVT and TMT A by Group 
 
Measure 
 
Group 
 
Mean 
Standard 
Deviation 
 
Sample Size 
PVT Non-Obese 265.81 35.464 44 
 Obese 270.90 34.842 58 
TMT A Non-Obese 31.20 10.364 44 
 Obese 31.28 11.472 58 
 
Preliminary RM-ANOVA tests were conducted to determine if there were 
differences in PVT and TMT A scores by BMI group following CPAP treatment without 
adjusting for age and hypertension. Results from the RM-ANOVA indicate that there was 
not a statistically significant main effect for CPAP treatment over time on PVT scores 
without adjusting for age and hypertension F (2, 200) = 2.220, p > .05, ηp2 = .022. 
Additionally, without adjusting for age and hypertension there was not a statistically 
significant interaction between BMI and CPAP treatment over time F (2, 200) = .849, p > 
.05, ηp2 = .008. Finally, no statistically significant differences were found between obese 
and non-obese participants on PVT scores over time F (1, 100) = .650, p > .05, ηp2 = 
.002. There was a statistically significant main effect for CPAP treatment over time on 
TMT A scores F (2, 200) = 11.126, p < .001, ηp2 = .100, such that scores decreased over 
time, which indicates improved performance. There was not a statistically significant 
interaction between BMI and CPAP treatment over time F (2, 200) = .358, p > .05, ηp2 = 
.004, and there were no statistically significant differences between obese and non-obese 
participants on the TMT A over time without adjusting for age and hypertension F (1, 
100) = .742, p > .05, ηp2 = .001. 
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RM-ANCOVA tests were conducted to determine if BMI impacted performance 
on PVT and TMT A scores following CPAP treatment after adjusting for age and 
hypertension. Covariates were age and presence of hypertension.  Table 11 provides a 
descriptive summary of PVT scores among BMI groups. There was not a statistically 
significant main effect for CPAP treatment over time on PVT scores F (2, 196) = .594, p 
= > .05, ηp2 = .006. Additionally, there was not a statistically significant interaction 
between BMI and CPAP treatment over time for PVT scores F (2, 196) = 1.079, p > .05, 
ηp
2 = .011, nor was there a statistically significant difference between obese and non-
obese participants on PVT scores over time F (1, 98) = 2.121, p > .05, ηp2 = .021. Figure 
1 displays PVT scores over time by BMI group.  
Table 11 
 
Descriptive Statistics for PVT at Baseline, 3-Month, and 6-Month Follow-Up 
by Group 
 
Measure 
 
Group 
 
Mean Score 
Standard 
Deviation 
 
Sample Size 
Baseline PVT Non-Obese 265.81 39.97 44 
 Obese 270.90 34.84 58 
3-Month PVT Non-Obese 260.62 30.08 44 
 Obese 265.12 34.93 58 
6-Month PVT Non-Obese 265.87 31.65 44 
 Obese 264.81 35.66 58 
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Figure 1 
 
 
Table 12 provides a descriptive summary of TMT A scores among BMI groups. 
Results from the RM-ANCOVA indicate that after adjusting for age and hypertension 
there was not a statistically significant main effect for CPAP treatment over time on TMT 
A scores F (2, 196) = 1.482, p > .05, ηp2 = .015. Further, there was not a statistically 
significant interaction between BMI and CPAP treatment over time for TMT A scores F 
(2, 196) = .310, p > .05, ηp2 = .003, nor were there statistically significant differences 
between obese and non-obese participants on TMT A scores over time F (1, 98) = .253, p 
> .05, ηp2 = .003. Figure 2 Displays TMT A scores over time by BMI group. Taken 
together, analyses surrounding TMT A scores indicate that there were statistically 
significant differences in performance following CPAP treatment, such that performance 
improved; however, these differences were no longer significant after adjusting for age 
and hypertension. 
 76 
Table 12 
 
Descriptive Statistics for TMT A at Baseline, 3-Month, and 6-Month Follow-Up 
by Group 
 
Measure  Group 
 
Mean 
Score 
Standard 
Deviation 
 
Sample Size 
Baseline TMT A Non-Obese 31.20 10.34 44 
 Obese 31.28 11.48 58 
3-Month TMT A Non-Obese 29.57 11.02 44 
 Obese 28.36 9.87 58 
6-Month TMT A Non-Obese 28.04 10.42 44 
 Obese 27.24 10.96 58 
 
Figure 2 
 
 
 Hypothesis II. Preliminary analyses were conducted to determine if differences 
in PASAT and TMT B scores at baseline existed between obese and non-obese 
participants without adjusting for age and hypertension. Results of the preliminary 
ANOVA indicate that there was not a statistically significant main effect of BMI on 
PASAT scores F (1, 100) = .601, p > .05, ηp2 = .006. There was, however, a statistically 
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significant main effect of BMI on TMT B scores F (1, 100) = 5.835, p < .05, ηp2 = .055, 
such that obese individuals tended to take less time to complete the task than non-obese 
individuals. Better performance on the TMT B is indicated by less time; thus, results of 
this analysis are not in the predicted direction.  
 ANCOVA’s were performed to determine if obese and non-obese participants 
demonstrated differences on baseline PASAT and TMT B scores after adjusting for age 
and hypertension. Table 13 provides a descriptive summary of PASAT and TMT B 
scores among BMI groups. After adjustment for covariates, no statistically significant 
main effect of BMI was found F (1, 98) = .033, p > .05, ηp2 = .000.  
Table 13 
 
Descriptive Statistics for PASAT and TMT B by Group 
 
Measure 
 
Group 
 
Mean Score 
Standard 
Deviation 
 
Sample Size 
PASAT Non-Obese 134.67 44.47 44 
 Obese 141.57 44.57 58 
TMT B Non-Obese 78.16 29.73 44 
 Obese 64.38 22.51 58 
 
An additional ANCOVA was performed to determine if differences existed 
between obese and non-obese participants on baseline TMT B scores after adjusting for 
age and hypertension. No statistically significant main effect of BMI was found F (1, 98) 
= 2.520, p > .05, ηp2 = .025 after adjusting for age and hypertension. Thus, with the 
inclusion of covariates, differences in TMT B performance between BMI groups did not 
reach statistical significance. 
RM-ANOVA tests were conducted to determine if differences existed in PASAT 
and TMT B scores between obese and non-obese participants following CPAP treatment 
without adjusting for age and hypertension. Results from the RM-ANOVA indicate that 
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there was a statistically significant main effect for CPAP treatment over time on PASAT 
scores F (2, 200) = 31.308, p < .001, ηp2 = .238, such that scores improved over time. 
Additionally, without adjusting for age and hypertension there was not a statistically 
significant interaction between BMI and CPAP treatment over time F (2, 200) = .285, p > 
.05, ηp2 = .003, nor were there statistically significant differences between BMI groups on 
PASAT scores following CPAP treatment F (1,100) = .265, p > .05, ηp2 = .012. There 
was a statistically significant main effect for CPAP treatment over time on TMT B scores 
F (2, 200) = 7.200, p < .001, ηp2 = .067, such that scores improved over time. However, 
there was not a statistically significant interaction between BMI and CPAP treatment 
over time F (2, 200) = 2.777, p > .05, ηp2 = .027, nor was there a statistically significant 
difference between obese and non-obese participants on the TMT B over time F (1, 100) 
= 2.318, p > .05, ηp2 = .023 without adjusting for age and hypertension. 
RM-ANCOVA tests were conducted to determine if BMI impacted performance 
on PASAT and TMT B scores following CPAP treatment after adjusting for age and 
hypertension. Table 14 provides a descriptive summary of PASAT scores among BMI 
groups. Results indicate that there was not a statistically significant main effect for CPAP 
treatment over time on PASAT scores F (2, 196) = 1.032, p > .05, ηp2 = .010. 
Additionally, there was not a statistically significant interaction between BMI and CPAP 
treatment over time for PASAT scores F (2, 196) = .509, p > .05, ηp2 = .005, nor was 
there a statistically significant difference between obese and non-obese participants on 
PASAT scores over time F (1, 98) = .238, p > .05, ηp2 = .002. Figure 3 demonstrates 
PASAT scores over time by BMI group. While there were statistically significant 
differences in PASAT scores following CPAP treatment, and a statistically significant 
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interaction between BMI and PASAT scores over time in the preliminary RM-ANOVA 
models, these differences were no longer statistically significant when age and 
hypertension were included as covariates. 
Table 14 
 
Descriptive Statistics for PASAT at Baseline, 3-Month, and 6-Month Follow-Up 
by Group 
 
Measure 
 
Group 
 
Mean Score 
Standard 
Deviation 
 
Sample Size 
Baseline 
PASAT Non-Obese 134.67 44.47 44 
 Obese 141.57 44.57 58 
3-Month 
PASAT Non-Obese 145.91 43.74 44 
 Obese 156.25 34.47 58 
6-Month 
PASAT Non-Obese 151.12 42.71 44 
 Obese 159.93 36.63 58 
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Figure 3 
 
Table 15 provides a descriptive summary of TMT B scores among BMI groups. 
The RM-ANCOVA results indicate that there was not a statistically significant main 
effect for CPAP treatment over time on TMT B scores F (2, 196) = 1.123, p > .05, ηp2 = 
.011. Additionally, there was not a statistically significant interaction between BMI and 
CPAP treatment over time for TMT B scores F (2, 196) = 2.372, p >.05, ηp2 = .024, nor 
were there statistically significant differences between obese and non-obese participants 
on TMT B scores over time F (1, 98) = .410, p > .05, ηp2 = .004. Figure 4 demonstrates 
TMT B scores over time by BMI group. Taken together, these results indicate that while 
preliminary models showed statistically significant differences in TMT B scores 
following CPAP treatment, these differences did not reach significance after adjusting for 
age and hypertension.  
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Table 15 
 
Descriptive Statistics for TMT B at Baseline, 3-Month, and 6-Month Follow-Up 
by Group 
 
Measure  Group 
 
Mean 
Score 
Standard 
Deviation 
 
Sample Size 
Baseline TMT B Non-Obese 76.91 29.89 44 
 Obese 64.38 22.51 58 
3-Month TMT B Non-Obese 66.16 22.46 44 
 Obese 62.31 27.55 58 
6-Month TMT B Non-Obese 67.60 29.06 44 
 Obese 61.44 29.79 58 
 
Figure 4 
 
 
 Hypothesis III. Preliminary ANOVA’s were conducted to determine if there 
were differences in HVLT Total and Delayed Recall scores between obese and non-obese 
participants without adjusting for age and hypertension. Results of the preliminary 
ANOVA’s indicate that there was not a statistically significant main effect of BMI on 
HVLT Total Recall scores F (1, 100) = .451, p > .05, ηp2 = .004. Additionally, there was 
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not a statistically significant main effect of BMI on HVLT Delayed Recall scores without 
adjusting for age and hypertension F (1, 100) = 2.891, p > .05, ηp2 = .028.  
 ANCOVA’s were performed to determine if differences existed between obese 
and non-obese participants on baseline HVLT Total Recall and Delayed Recall scores. 
Table 16 provides a descriptive summary of HVLT Total Recall and HVLT Delayed 
Recall scores among BMI groups. After adjustment by covariates, no statistically 
significant main effect of BMI was found F (1, 98) = .010, p > .05, ηp2 = .000. An 
additional ANCOVA was performed to determine if differences existed between obese 
and non-obese participants on baseline HVLT Delayed Recall scores. After adjustment 
by covariates, no statistically significant main effect of BMI was found F (1, 98) = 1.303, 
p > .05, ηp2 = .013.  
Table 16 
 
Descriptive Statistics for HVLT Total Recall and HVLT Delayed Recall Scores 
by Group 
 
Measure 
 
Group 
 
Mean Score 
Standard 
Deviation 
 
Sample Size 
HVLT Total Non-Obese 25.61 4.64 44 
 Obese 26.27 5.08 58 
HVLT 
Delayed Non-Obese 8.73 2.58 44 
 Obese 9.60 2.58 58 
 
RM-ANOVA tests were conducted to determine if obese and non-obese 
participants displayed differences in HVLT Total and Delayed Recall scores following 
CPAP treatment without adjusting for age and hypertension. Results from the RM-
ANOVA indicate that there was a statistically significant main effect for CPAP treatment 
over time on HVLT Total Recall scores F (2, 200) = 36.225, p < .001, ηp2 = .266, such 
that scores increased over time indicating better performance. There was not a 
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statistically significant interaction between BMI and CPAP treatment over time F (2, 
200) = .068, p > .05, ηp2 = .001. No statistically significant differences between obese and 
non-obese participants were found in HVLT Total Recall scores F (1,100) = .376, p > 
.05, ηp2 = .008. There was a statistically significant main effect for CPAP treatment over 
time on HVLT Delayed Recall scores F (2, 200) = 9.621, p < .001, ηp2 = .088; however, 
there was not a statistically significant interaction between BMI and CPAP treatment 
over time on HVLT Delayed Recall scores F (2, 200) = .790, p > .05, ηp2 = .008. Finally, 
there was not a statistically significant difference between obese and non-obese 
participants on HVLT Delayed Recall scores over time without adjusting for age and 
hypertension F (1, 100) = 2.903, p > .05, ηp2 = .028. 
RM-ANCOVA tests were conducted to determine if BMI impacted performance 
on HVLT Total Recall and HVLT Delayed Recall scores following CPAP treatment. 
Table 17 provides a descriptive summary of HVLT Total Recall scores among BMI 
groups. Results from the RM-ANCOVA indicate that there was not a statistically 
significant main effect for CPAP treatment over time on HVLT Total Recall scores F (2, 
196) = 1.219, p > .05, ηp2 = .012. There was not a statistically significant interaction 
between BMI and CPAP treatment over time for HVLT Total Recall scores F (2, 196) = 
.100, p > .05, ηp2 = .001, and was there not a statistically significant difference between 
obese and non-obese participants on HVLT Total Recall scores over time F (1, 98) = 
.028, p > .05, ηp2 = .000. Figure 5 demonstrates HVLT Total Recall scores over time by 
BMI group. Overall, there was a statistically significant difference in HVLT Total Recall 
scores following CPAP treatment, such that scores improved over time; however, these 
 84 
differences did not reach significance when age and hypertension were included as 
covariates in the models.  
Table 17 
 
Descriptive Statistics for HVLT Total Recall at Baseline, 3-Month, and 6-
Month Follow-Up by Group 
 
Measure 
 
Group 
 
Mean Score 
Standard 
Deviation 
 
Sample Size 
Baseline HVLT 
Total Non-Obese 25.61 4.64 44 
 Obese 26.27 5.08 58 
3-Month HVLT 
Total Non-Obese 25.34 4.45 44 
 Obese 26.21 5.17 58 
6-Month HVLT 
Total Non-Obese 27.95 5.04 44 
 Obese 28.83 5.04 58 
 
Figure 5 
 
Table 18 provides a descriptive summary of HVLT Delayed Recall scores among 
BMI groups. RM-ANCOVA results indicate that there was not a statistically significant 
main effect for CPAP treatment over time on HVLT Delayed Recall scores F (2, 196) = 
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1.332, p > .05, ηp2 = .013. Further, there was not a statistically significant interaction 
between BMI and CPAP treatment over time for HVLT Delayed Recall scores F (2, 196) 
= .993, p > .05, ηp2 = .013, nor were there statistically significant differences between 
obese and non-obese participants on HVLT Delayed Recall scores over time F (1, 98) = 
.996, p > .05, ηp2 = .010. Figure 6 demonstrates HVLT Delayed Recall scores over time 
by BMI group. Considered with the preliminary analysis, results indicate that there were 
statistically significant differences in HVLT Delayed Recall scores following CPAP 
treatment, such that performance improved over time; however, these differences did not 
reach significance after adjusting for age and hypertension.  
Table 18 
 
Descriptive Statistics for HVLT Delayed Recall at Baseline, 3-Month, and 6-
Month Follow-Up by Group 
Measure Group Mean Score Standard Deviation Sample Size 
Baseline HVLT 
Delayed Non-Obese 8.73 2.58 44 
 Obese 9.60 2.58 58 
3-Month HVLT 
Delayed Non-Obese 8.89 2.59 44 
 Obese 9.79 2.19 58 
6-Month HVLT 
Delayed Non-Obese 9.72 2.45 44 
 Obese 10.20 2.44 58 
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Figure 6 
 
 
Summary  
 
 Chapter IV presented the results of preliminary and primary data analyses for the 
present study. Differences between obese and non-obese participants in baseline 
cognitive performance and cognitive performance following six months of CPAP 
treatment were explored. Results, limitations of the present study, and future directions 
for research in this area will be discussed in Chapter V.  
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Chapter V: Discussion 
Results 
 Preliminary Analyses. Preliminary analyses were conducted to determine if there 
were differences between obese and non-obese participants on key demographic 
variables. Obese and non-obese participants did not differ in terms of years of education, 
AMNART, BDI-II, and HADS scores. However, there was a statistically significant 
difference between the two groups in age, such that obese participants were younger. 
While obese and non-obese participants demonstrated differences in age, the ANCOVA 
models were adjusted for age, and thus, these differences did not impact the final 
analyses. 
 Hypothesis I. The first hypothesis predicted there would be differences between 
obese and non-obese participants on baseline PVT and TMT A scores, as well as 
differences between groups following six months of CPAP treatment, such that obese 
individuals would demonstrate poorer performance. Results indicate there were not 
statistically significant differences between obese and non-obese participants on PVT and 
TMT A scores at baseline. The same result was found after adjusting for age and 
hypertension. Finally, there were no statistically significant differences between obese 
and non-obese participants on PVT and TMT A scores over time. This result was the 
same before and after adjusting for age and hypertension. 
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 There are several hypotheses related to the lack of statistically significant 
differences between obese and non-obese participants on measures of attention at 
baseline and following treatment, some of which relate to the study design and analyses 
and will be discussed in the following section. Another hypothesis relates to the construct 
of attention and the manner in which it was measured in the present study. Attention was 
measured using both the PVT, which  is a measure of sustained attention and reaction 
time, as well as the TMT A, which measures immediate focus, sequencing, and to some 
extent, visual processing. No previous studies have analyzed the relationship between 
obesity and performance on the PVT specifically; therefore, comparisons between the 
results of this study and previous research regarding this measure are not possible. 
However, a study conducted by Gunstad et al. (2010) suggests that obesity does not 
impact performance on the TMT A, and that obese individuals may demonstrate better 
performance than their non-obese counterparts: These researchers found that increasing 
obesity was associated with better performance on the TMT A as age increased. The 
divergent results found in the present study and by Gunstad et al. (2010) suggest that the 
relationship between obesity and attention – particularly the aspects of attention 
measured by the TMT A – is unclear. Continued research in this area is warranted to 
clarify whether or not obesity negatively impacts attention.   
 Hypothesis II. Hypothesis Two predicted there would be differences between 
obese and non-obese participants on baseline PASAT and TMT B scores, in addition to 
differences between these groups following six months of CPAP treatment. It was 
predicted that obese individuals would demonstrate poorer performance at baseline and 
following six months of treatment compared to non-obese individuals. Results indicate 
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there were no statistically significant differences between obese and non-obese 
participants on PASAT scores. This result was the same after adjusting for age and 
hypertension. There were statistically significant differences between obese and non-
obese participants on baseline TMT B scores, such that obese individuals performed 
better on this measure. However, these results did not reach significance after adjusting 
for age and hypertension. In addition, there were no between group differences on 
PASAT and TMT B scores over time both with and without adjusting for age and 
hypertension.  
 Overall, the results lead to a rejection of hypothesis two. In general, obese 
individuals demonstrated better performance on PASAT and TMT B scores; however, 
any statistically significant differences between groups were no longer significant after 
adjusting for age and hypertension. Therefore, since the non-obese group was older than 
the obese group, the differences between groups appear to be more attributable to age 
than BMI. Indeed, working memory abilities are particularly susceptible to decline with 
age (Strauss, Sherman, & Spreen, 2007). Nevertheless, the lack of differences between 
obese and non-obese participants on the PASAT and TMT B was unexpected.  
 The definition of obesity used in the present study could be related to this 
unpredicted finding. Obesity was defined solely by BMI, which is not an ideal measure, 
as it does not distinguish fat mass from lean mass, nor does it provide information 
regarding the distribution of fat. Other researchers have used measures of obesity 
including WHR and WC, as they provide information on upper body fat, which is highly 
correlated with the negative health consequences of obesity (Kopelman, 2000). Some 
evidence to support the hypothesis that differences may not have been detected between 
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obese and non-obese persons based on BMI is evident in the literature. For example, 
Gunstad et al. (2010) used two measures of obesity in their study, including BMI and 
WHR. They found that higher WHR was associated with poorer performance on an 
executive functioning task (i.e., cognitive flexibility), but the same was not true for 
higher BMI. Thus, it is possible that an alternative measure of obesity could have yielded 
different results in the present study. Unfortunately, this additional measure of obesity 
could not be attained for this project, but considering the limitations of using BMI as the 
only measure of obesity, future research should include supplemental measures such as 
WHR or WC.  
 Hypothesis III. Hypothesis Three predicted there would be differences between 
obese and non-obese participants on HVLT Total Recall and Delayed Recall scores at 
baseline and following six months of CPAP treatment, such that obese participants would 
demonstrate poorer performance. Results indicate there were no statistically significant 
differences between obese and non-obese participants on HVLT Total Recall or Delayed 
Recall scores at baseline. These results remained after adjusting for age and hypertension. 
Additionally, there were no statistically significant between group differences on HVLT 
Total Recall or Delayed Recall scores following CPAP treatment both with and without 
adjusting for hypertension.  
Taken together, the results lead to a rejection of hypothesis three. The extant 
literature pertaining to obesity and memory deficits suggests there is a clear relationship 
between obesity and visual and verbal memory deficits; thus, an explanation for the lack 
of differences between BMI groups in the present study is not entirely clear. There is 
evidence to suggest that sex differences moderate the relationship between obesity and 
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memory impairments, and sex differences were not accounted for in the present study. It 
was hoped to include sex as a covariate in the final models, but this was not possible due 
to a significant interaction between obesity and sex, which violates an assumption of 
ANCOVA. An alternative method for analyzing the data could have been to include sex 
as a second factor in the models; however, this was beyond the purview of the present 
study. Nevertheless, the significant interaction between obesity and sex does suggest that 
there could be differences between obese and non-obese men and women, and this should 
be explored in future research. Another hypothesis for the lack of differences between 
obese and non-obese participants on verbal memory in the present study, again, concerns 
the way obesity was measured. There is evidence to suggest that memory impairments in 
obese persons may be more pronounced for individuals with abdominal obesity (Gunstad 
et al., 2010).   
 Secondary Findings. While the present study’s hypotheses concerned differences 
in cognitive functioning between obese and non-obese participants at baseline and 
following treatment, the analyses provided secondary results surrounding the overall 
sample’s cognitive functioning over time. Though these findings were of lesser 
importance in the present study, they were unexpected, and thus, warranted exploration. 
The secondary results indicate there was not a statistically significant within group 
difference on PVT scores following six months of CPAP treatment, both with and 
without adjusting for age and hypertension. There was a statistically significant within 
group difference on TMT A scores following CPAP treatment, such that scores improved 
over time; however, these differences did not reach statistical significance after adjusting 
for age and hypertension. Similarly, there were statistically significant within group 
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differences on PASAT, TMT B, HVLT Total Recall, and Delayed scores following six 
months of CPAP treatment, such that scores improved over time. However, these results 
did not reach significance after adjusting for age and hypertension. 
The secondary findings are surprising given the research supporting the efficacy 
of CPAP treatment in mitigating many cognitive deficits associated with OSAS. One 
hypothesis for the lack of within group differences over time concerns the sample’s 
baseline level of cognitive functioning. Participants’ age and education adjusted mean 
scores across cognitive measures were in the Average Range. Thus, taken together the 
sample did not demonstrate the cognitive deficits typically associated with OSAS, and 
therefore, had less room to improve in their performance over time. Another possible 
explanation for these results is that the persons involved in the present study had certain 
protective factors (e.g., many years of education, higher than average household income, 
access to excellent healthcare) that mitigated the neurocognitive sequelae common 
among individuals with OSAS. Additionally, participants were recruited for the study 
immediately following their diagnosis of OSAS. While it is unclear how long participants 
had OSAS prior to bring diagnosed, it is possible that they were diagnosed and treated 
early enough to prevent the deleterious cumulative effects of sleep fragmentation and 
oxygen deprivation on their cognitive functioning. Finally, only participants who were 
minimally compliant to the CPAP were included in the study. There could be important 
differences between individuals who adhered to treatment and those who did not such as 
education, motivation, and/or severity of OSAS, all of which could have impacted 
cognitive test performance. 
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Limitations 
 This study has several limitations. First, the majority of the sample was 
overweight to obese, with only 9 % of the sample falling in the normal weight BMI 
classification. Therefore, many individuals in the “non-obese” group were actually 
overweight, and thus, comparisons between groups might be more accurately described 
as obese vs. overweight. Unfortunately, due to the analyses used, BMI groups needed to 
be close to equivalent; therefore, it would not have been possible to use more discrete 
categories for BMI due to the fact that so few participants could be classified as normal 
weight. Analyses that do not require discrete categorizations of BMI, such as regression, 
might be more appropriate for future research in this area.  
 In addition to the problems with the categorization of BMI in the present study, 
the use of BMI as a measure of obesity, in and of itself, is problematic. BMI, though 
widely used to measure obesity, is not a highly sensitive measurement in that it does not 
differentiate between fat mass and lean mass, nor does it indicate the distribution of fat. 
Further, alternative measures such as WHR or WC, which measure abdominal obesity, 
have demonstrated greater sensitivity in detecting cognitive differences between obese 
and non-obese individuals. Thus, WHR and WC may be more appropriate measures of 
obesity for questions related to cognitive deficits in obese persons and should at least be 
used as a supplement to BMI in future research.  
  Another limitation of the present study pertains to the inclusion criteria. Only 
individuals who were minimally compliant to CPAP treatment were included in the 
study. This decision was made in order to eliminate potential confounding effects of 
limited CPAP use on longitudinal research questions. While it was necessary to control 
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for this variable, only including individuals who were minimally compliant with CPAP 
treatment significantly reduced the sample size. Additionally, as mentioned previously, 
individuals who adhered to CPAP treatment may have possessed unique traits that could 
have impacted cognitive test performance. Rather than only including individuals who 
were compliant with treatment, it may have been a better choice to statistically control for 
CPAP usage in the analyses.  
 In addition to the limitations surrounding the inclusion criteria, the 
generalizability of the sample is somewhat limited. The sample in the present study was 
highly educated, with a mean level of education that included four years of post-
secondary study. Additionally, over half of the sample had a household income well 
above the median household income in the United States. Thus, the majority of the 
sample could afford and had access to the excellent healthcare offered at National Jewish 
Health, which is a highly regarded respiratory hospital and research center. Overall, there 
were some unique characteristics about the sample that do not generalize to the larger 
population of persons with OSAS, and these differences could have impacted the results.  
 The statistical analyses used in the present study are perhaps one of its largest 
limitations. It was originally proposed to use Multivariate Hierarchical Linear Modeling 
(MHLM). There would have been several advantages to using this approach, including 
accounting for the lack of independence that is inherent in hierarchically organized, 
longitudinal data. Further, this approach would have allowed for an analysis of growth 
trajectories and any differences that may have existed in growth over time between obese 
and non-obese participants. Snijders and Bosker (1999) highlighted several advantages of 
using MHLM, including the following: 1) it is possible to draw conclusions about the 
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correlations between the dependent variables; specifically, the degree to which the 
correlations depend on the individual and group levels; 2) the tests of specific effects for 
particular dependent variables are more powerful in multivariate analysis (i.e., the 
standard errors are reduced); 3) testing whether the impact of a predictor variable on a 
certain dependent variable is larger than the impact on another dependent variable when 
the data were observed on the same individual is only possible with multivariate analysis; 
and 4) if a researcher would like to perform a single test of the combined effect of a 
predictor variable on several dependent variables, multivariate analysis is compulsory. 
Though MHLM likely would have been a more sophisticated way to analyze the data, the 
complexities involved in this approach were beyond the scope of this project.  
 Although the analyses used in the present study were adequate for testing the 
hypotheses, they presented several problems due to strict assumptions. First, when using 
ANCOVA, datasets cannot have missing values. As a result of this assumption, missing 
values were replaced using EM. While this approach is acceptable, it is not ideal and can 
result in decreased variation and underestimated standard error. Alternative approaches, 
such as multilevel modeling, do not have this missing data requirement and may be a 
better option for longitudinal datasets with missing values. Second, ANCOVA has 
stringent requirements surrounding covariates, which resulted in the elimination of 
several potentially meaningful covariates in the models (e.g. sex, years of education, 
presence of diabetes, etc,). Third, as previously mentioned, ANCOVA requires relatively 
equivalent sample sizes within groups. As a result of this requirement, it was not possible 
to create several groups that included more than two categories of BMI (i.e., normal 
weight, overweight, obese, morbidly obese). Thus, the majority of the non-obese group 
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included individuals who were technically overweight. Being restricted to only having 
two BMI groups (i.e., obese and non-obese) reduced the naturally occurring variation in 
BMI as a continuous variable, which could have impacted the findings. Finally, due to 
correlations among some of the outcome variables, it was not possible to use a 
multivariate analysis of covariance (MANCOVA) or repeated measures multivariate 
analysis of covariance (RM-MANCOVA), and as a result, several ANCOVA and RM-
ANCOVA models were used. Though MANCOVA and RM-MANCOVA were not 
appropriate analyses for this study, modeling several ANCOVA and RM-ANCOVA’s 
may have inflated the Type I error rate (Tabachnick & Fidell, 2007).  
 Another problem related to the data analyses used in the present study involves 
the level of power and strength of effect sizes, both of which were very small across 
analyses. As power is the probability of correctly rejecting the null hypothesis when the 
alternative hypothesis is true, it is important to have adequate power in order to detect 
differences if they are indeed present (Tabachnick & Fidell, 2007). Given the extremely 
low statistical power of the analyses used in this study, the likelihood of making Type II 
errors was high. It is possible that differences did exist between obese and non-obese 
groups in different areas of cognitive functioning, but the analyses did not have enough 
power to detect them. Given that archival data was used, it was not possible to recruit a 
sample large enough to achieve adequate power.  
Future Directions 
 While the hypotheses of the present study were not supported, there is much 
evidence to support the theory that obese individuals with OSAS demonstrate greater 
cognitive impairment than normal weight individuals with OSAS, and research in this 
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area should continue. Due to the inadequate power of the analyses used in the present 
study, a recommendation for future studies is to address differences in neurocognitive 
functioning between obese and non-obese individuals with OSAS using a larger sample 
size. A larger sample size would increase statistical power and reduce the likelihood of 
making a Type II error, thus increasing the possibility of detecting differences between 
obese and non-obese individuals if they do exist. In addition to a larger sample, future 
studies should recruit participants who are representative of the larger population of 
individuals with OSAS in order for the results to be generalizable.  
 Another recommendation for future research in this area is to use WHR or WC as 
a supplemental measure of obesity. BMI in and of itself is an inadequate measure of 
obesity, or at least abdominal obesity, which appears to be more closely related to the 
physical and neurocognitive problems associated with obesity. Having WHR or WC 
would allow for more nuanced analyses and conclusions regarding how the distribution 
of fat may contribute to different aspects of cognitive dysfunction.  
 Considering evidence in the literature pointing to sex differences in cognitive 
functioning between obese and non-obese individuals, as well the significant interaction 
found between obesity and sex when testing assumptions for the present study’s analyses, 
it is recommended that future research analyze this relationship. It will be important to 
determine the extent to which sex moderates the relationship between obesity and 
cognitive dysfunction in the OSAS population, as this knowledge could lead to different 
gradations in treatment recommendations not only for obese and non-obese persons, but 
also for males and females.  
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Conclusions 
The objective of this study was to examine differences in cognitive functioning 
between obese and non-obese individuals with OSAS. Specifically, this study aimed to 
identify differences between obese and non-obese patients with OSAS both at baseline 
and over six months of CPAP treatment. This study was the first of its kind and added to 
the literature concerning the relationships between obesity, OSAS, and 
neuropsychological functioning. Though this study did not find statistically significant 
differences in cognitive functioning between obese and non-obese persons with OSAS 
after controlling for age and hypertension, there were methodological limitations that 
could have precluded the detection of such differences. Considering the conflicting 
evidence suggesting obesity could negatively impact the cognitive functioning of 
individuals with OSAS, continued research in this area is warranted.  
 99 
References 
Adams, K.F., Schatzkin, A., Harris, T.B., Kipnis, V., Mouw, T., Vallard-Barbash, R., et  
al. (2006). Overweight, obesity, and mortality in a large prospective cohort of 
persons 50 to 71 years old. New England Journal of Medicine, 355, 763-778. 
Aloia, M.S. (2012). [motivating adherence to PAP in obstructive sleep apnea]. 
Unpublished raw  
data.  
Aloia, M.S., Arnedt, J.T., Davis, J.D., Riggs, R.L., & Byrd, D. (2004).  
Neuropsychological sequelae of obstructive sleep apnea-hypopnea syndrome: A 
critical review. Journal of International Neuropsychological Society, 10, 772-785.  
Altfas, J. (2002). Prevalence of attention deficit/hyperactivity disorder among adults in  
obesity treatment. BMC Psychiatry, 2, 1-8.  
American Academy of Sleep Medicine Task Force. (1999). Sleep-related breathing  
disorders in adults: Recommendations for syndrome definition and measurement 
techniques in clinical research. Sleep, 22, 667-689.  
American Psychiatric Association. (2000). Diagnostic and statistical manual of mental  
 
disorders (4th ed., text rev.). Washington, DC: Author. 
 
American Thoracic Society. (1994). Sleep-related breathing disorders in adults:  
Recommendations for syndrome definitions and measurement techniques in 
clinical research. Sleep, 22, 667-689.  
Arnau, R.C., Meagher, M.P., Norris, P., & Bramson, R. (2001). Psychometric evaluation  
 
of the Beck Depression Inventory-II with primary care medical patients. Health  
 
Psychology, 20, 112-119. 12 
 100 
 
Backman, L., Wahlin, A., Small, B.J., Herlitz, A., Winblad, B., & Fratiglioni, L. (2004).  
Cognitive functioning in aging and dementia: The Kungsholmen Project. Aging, 
Neuropsychology and Cognition, 11, 212-244.  
Bardwell, W.A., Ancoli-Israel, S., Berry, C.C., & Dimsdale, J.E. (2001).  
Neuropsychological effects of one-week continuous positive airway pressure 
treatment in patients with obstructive sleep apnea: A placebo-controlled study. 
Psychosomatic Medicine, 63, 579-584.  
Battle, E.K., & Brownell, K.D. (1997). Confronting a rising tide of eating disorders and  
obesity: Treatment vs. prevention and policy. Addictive Behaviors, 21, 755-765.  
Beck, A.T., Steer, R.A., Brown, G.K. (1996). Manual for the Beck Depression Inventory– 
 
II. San Antonio, TX: Psychological Corporation. 
 
Bédard, M., Montplaisir, J., Malo, J., Richer, F., & Rouleau, I. (1993). Persistent  
neuropsychological deficits and vigilance impairment in sleep apnea syndrome 
after treatment with continuous positive airway pressure (CPAP). Journal of 
Clinical and Experimental Psychology, 15, 330-341.  
Bédard, M., Montplaisir, J., Richer, F., Rouleau, I., & Malo, J. (1991). Obstructive sleep  
apnea syndrome: Pathogenesis of neuropsychological deficits. Journal of Clinical 
and Experimental Psychology, 13, 950-964.  
Beebe, D.W., Groesz, L., Wells, C., Nichols, A., McGee, K. (2003).  The  
neuropsychological effects of obstructive sleep apnea: A meta-analysis of norm-
referenced and case-controlled data. Sleep, 26, 298-307. 
Benedict, R.H.B., Schretlen, D., Groninger, L., Dobraski, M., & Brandt, J. (1998). The  
 
 101 
Hopkins Verbal Learning Test-Revised: Normative data and analysis of interform  
 
and test-retest reliability. The Clinical Neuropsychologist, 12, 43-55.  
 
Benton, A.L. (1946). A Visual Retention Test for Clinical Use. New York: Psychological  
Corporation.  
Benton, A. (1968). Der Benton Test. Bern: Hans Huber Verlag. 
Berry, D.T.R., Webb, W.B., Block, A.J., Bauer, R.M., & Sweitzer, D.A. (1986).  
Nocturnal hypoxemia and neuropsychological variables. Journal of Clinical 
Experimental Neuropsychology, 8, 229-238.  
Beydoun, M.A., Beydoun, H.A., & Wang, Y. (2008). Obesity and central obesity as risk  
factors for dementia and its subtypes: A systematic review and meta-analysis. 
Obesity Reviews, 9, 204-218.  
Bhatnager, D., Anand, I.S., Durrington, P.N., Patel, D.J., Wander, G.S., Machness, M.I.,  
et al. (1995). Coronary risk factors in people from the Indian subcontinent living 
in west London and their siblings in India. Lancet, 345, 405-409.  
Bjelland, I., Dahl, A.A., Haug, T.T., & Nickermann, D. (2002). The validity of the  
 
Hospital Anxiety and Depression Scale: An updated literature review. Journal of  
 
Psychosomatic Medicine, 52, 69-77.  
 
Blessed G, Tomlinson BE, Roth M. (1968). The association between quantitative  
measures of dementia and of senile change in the cerebral grey matter of elderly 
subjects. British Journal of Psychiatry, 114, 797-811. 
Boeka, A.G., & Lokken, L. (2008). Neuropsychological performance of a clinical sample  
of extremely obese individuals. Archives of Clinical Neuropsychology, 23, 467-
474.  
 102 
Bornstein, R. A., Baker, G.B., Douglas, A.B. (1987). Short-term retest reliability of the  
Halstead-Reitan Battery in a normal sample. Journal of Nervous and Mental 
Disease, 175, 229-232. 
Bouchard, C. Tremblay, A., Després, J., Nadeau, A., Lupien, P., Thériault, G., et al.  
(1990). The response to long-term overfeeding in identical twins. New  
England Journal of Medicine, 322, 1477-1482.  
Brandt, J. (1991). The Hopkins Verbal Learning Test: Development of a new memory  
 
test with six equivalent forms. The Clinical Neuropsychologist, 5, 125-142.  
 
Brandt, J., & Benedict, R.H.B. (2001). Hopkins Verbal Learning Test-Revised. Odessa,  
 
FL: PAR. 
 
Chelune, G.J., Ortega, D., Linton, J.C., & Coustany, M.M. (1986). Personality and  
cognitive findings among patients electing gastroplasty for morbid obesity. 
International Journal of Eating Disorders, 5, 701-712.  
Chronicle, E.P., & MacGregor, N.A. (1998). Are PASAT scores related to mathematical 
 ability?  
Neuropsychological Rehabilitation, 8, 273-282. 
Campfield, L.A., Smith, F.J., Guisez, Y., Devos, R., & Burn, P. (1995). Recombinant  
mouse OB protein: Evidence for a peripheral signal lining adiposity and central 
neural networks. Science, 269, 546-549. 
Centers for Disease Control and Prevention, Overweight and Obesity. (2011, February).  
U.S. Obesity Trends: Trends by State 1985-2009. Retrieved March 1, 2011 from 
the Centers for Disease Control Website:   
http://www.cdc.gov/obesity/data/trends.html 
 103 
Cohen, R.A. (1993). The Neuropsychology of Attention. New York: Plenum Press.  
Colditz, G.A., Willett, W.C., Rotnitzky, A., Manson, J.E. (1995). Weight gain as a risk  
factor for clinical diabetes mellitus in women. Annals of Internal Medicine, 122, 
581-486.  
Colrain, J.L., Tomiyasu, U., Read, S., & Benson, D.F. (1984). Amnesia with  
hippocampal lesions after cardiopulmonary arrest. Neurology, 34, 679-681.  
Considine, R.B., Sinha, M.K., Heiman, M.L., Kriauciunas, A., Stephens, T.W., Nyce,  
M.R., et al. (1996). Serum immunoreactive-leptin concentrations in normal-
weight and obese humans. New England Journal of Medicine, 334, 292-295.  
Convit, A., Wolf, O.T., Tarshish, C., de  Leon, M. (2003). Reduced glucose tolerance is  
associated with poor memory performance and hippocampal atrophy among 
normal elderly. Proceedings of the National Academy of Sciences, 100, 2019-
2022. 
Cournot, M., Marquié, J.C., Ansiau, D., Martinaud, C., Fonds, H., Ferrieres, J., et al.  
(2006). Relation between body mass index and cognitive function in healthy 
middle-aged men and women. Neurology, 67, 1208-1214.  
Crawford, J.R., Obansawin, M.C., & Allen, K.M. (1998). PASAT and components of  
 
WAIS-R performance: Convergent and discriminant validity. Neuropsychological  
 
Rehabilitation, 8, 273-272.  
 
Dagenais, G.R., Yi, Q., Mann, J.F.E., Bosch, J., Pogue, J., & Yusuf, S. (2005). Prognostic  
impact of body weight and abdominal obesity in women and men with 
cardiovascular disease. American Heart Journal, 149, 54-60. 
Décary, A., Rouleau, I., & Montplaisir, J. (2000). Cognitive deficits associated with sleep  
 104 
apnea syndrome: A proposed neuropsychological test battery. Sleep 23, 1-13.  
Delis, D.C., Kramer, J.H., Kaplan, E., & Ober, B.A. (2000). California Verbal Learning  
Test – Second Edition, Adult Version. San Antonio, Texas: The Psychological 
Corporation.  
Dikman, S.S., Heaton, R.K., Grant, I., & Temkin, N.R. (1999). Test-retest reliability and  
practice effects of expanded Halstead-Reitan Neuropsychological Test Battery. 
Journal of the International Neuropsychological Society, 5, 346-356. 
Dinges, D.F., & Powell, J.W. (1985). Microcomputer analyses of performance on a  
 portable, simple visual RT task during sustained operations. Behavioral Research 
 Methods, Instruments, and Computers, 17, 652-655.  
Dinges, D.F., & Weaver, T. (2003). Effects of modafinil on sustained attention  
 performance and quality of life in OSA patients with residual sleepiness while 
 being treated with nCPAP. Sleep Medicine, 4, 393-402.  
Dorrian, J., Rogers, N.L., & Dinges, D.F. (2005). Psychomotor vigilance performance: 
 neurocognitive assay sensitive to sleep loss. In Kushida, C.A. (Ed). Sleep 
Deprivation:  Basic Science, Physiology, and Behavior. New York: Marcel Dekker.  
Elias, M.F., Elias, P.K., Sullivan, P.A., Wolf, P.A., D’Agostino, R.B. (2003). Lover  
cognitive function in the presence of obesity and hypertension: The Framingham 
Heart Study. International Journal of Obesity, 27, 260-268.  
Elias, M.F., Elias, P.K., Sullivan, P.A., Wolf, P.A., D’Agostino, R.B. (2005). Obesity,  
diabetes and cognitive deficit: The Framingham Heart Study. Neurobiology of 
Aging, 26S, S11-S16.  
Engleman, H., & Douglas, N.J. (1993). Cognitive effects and daytime sleepiness. Sleep,  
 105 
16, S79. 
Engleman, H.M., Douglas, N.J. (2004). Sleep 4: Sleepiness, cognitive function, and  
quality of life in obstructive sleep apnoea/hypopnoea syndrome. Thorax, 59, 618-
622.  
Engleman, H.M., Martin, S.E., Deary, I.J., & Douglas, N.J. (1994). Effect of continuous  
positive airway pressure treatment on daytime function in sleep 
apnoea/hypopnoea syndrome. Lancet, 343, 572-575. 
Engleman, H.M., Martin, S.E., Deary, I.J., & Douglas, N.J. (1997). Effect of CPAP  
therapy on daytime function in patients with mild sleep apnoea/hypopnoea 
syndrome. Thorax, 52, 114-119. 
Ferini-Strambi, L., Baietto, C., Gioia, P., Castaldi, C., Castronovo, C., Zucconi, M. et al.  
(2003). Cognitive dysfunction in patients with obstructive sleep apnea (OSA): 
partial reversibility after continuous positive airway pressure (CPAP). Brain 
Research Bulletin, 61, 87-92.  
Findley, L.J., Barth, J.T., Powers, D.C., Wilhoit, S.C., Boyd, D.G., & Suratt, P.M.  
(1986). Driving simulator performance in patients with sleep apnea. American 
Review of Respiratory Disease, 140, 529-530. 
Folstein, M.F., Folstein, S.E., & McHugh, P.R. (1975). “Mini-Mental State.” A practical  
method for grading the cognitive state of patients for the clinician. Journal of 
Psychiatric Research, 12, 189-198. 
Garfinkel, L. (1985). Overweight and cancer. Annals of Internal Medicine, 103, 1034- 
1060.  
Gay, P., Weaver, T., Loube, D., & Iber, C. (2006). Evaluation of positive airway pressure  
 106 
treatment for sleep related breathing disorders in adults.  Sleep, 29, 381-401.  
Girden, E. (1992). ANOVA: Repeated Measures. Newbury Park, CA: Sage.  
Greenberg, G.D., Watson, R.K., & Deptula, D. (1987). Neuropsychological dysfunction  
in sleep apnea. Sleep, 10, 254-262. 
Grober, E., Sliwinski, M., Korey, S.R. (1991). Journal of Clinical and Experimental  
 
Neuropsychology, 6, 933-949. 
 
Gronwell, D.M.A. (1977). Paced Auditory Serial Addition Task: A measure of recovery  
 
from concussion. Perceptual and Motor Skills, 44, 367-373.  
 
Gunstad, J., Benitez, A., Smith, J., Glickman, E., Spitznagel, M.B., Alexander, T., et al.  
(2008). Serum brain-derived neurotrophic factor is associated with cognitive 
function in healthy older adults. Journal of Geriatric Psychiatry Neurology, 21, 
166-170.  
Gunstad, J., Lhotsky, A., Wendell, C.R., Ferrucci, L., & Zonderman, A.B. (2010).  
Longitudinal examination of obesity and cognitive function: Results from the 
Baltimore Longitudinal Study of Aging. Neuroepidemiology, 34, 222-229.  
Gunstad, J., Paul, R.H., Cohen, R.A., Tate, D.F., & Gordon, E. (2006). Obesity is  
associated with memory deficits in young and middle-aged adults. Eating and 
Weight Disorders, 11, e15-e19. 
Gunstad, J., Paul, R.H., Cohen, R.A., Tate, D.F., Spitznagel, M.B., & Gordon, E. (2007).  
Elevated body mass index is associated with executive dysfunction in otherwise 
healthy adults. Comprehensive Psychiatry, 48, 57-61.  
Gunstad, J., Spitznagel, M.B., Keary, T.A., Glickman, E., Alexander, T., & Karrer, J.  
 107 
(2008). Serum leptin levels are associated with cognitive function in older adults. 
Brain Research, 1230, 233-236. 
Gustafson, D.R., Steen, B., Skoog, B. (2004). Body mass index and white matter lesions  
in elderly women. An 18-year longitudinal study. International Psychogeriatrics, 
16, 327-336. 
Harvey, J. (2007). Leptin: A diverse regulator of neuronal function. Journal of  
Neurochemistry, 100, 307-313.  
Hariri, A.R., Goldberg, T.E., Mattay, V.S., Kolachana, B.S., Callicott, J.H., Egan, M.F. et  
al. (2003). Brain-derived neurotrophic factor val66met polymorphism affects 
human memory-related hippocampal activity and predicts memory performance. 
The Journal of Neuroscience, 17, 6690-6694.  
Heaton, R.K. Wisconsin Card Sorting Test (WCST). Odessa: Psychological Assessment  
Resources.  
Hogervorst, E., Combrinck, M., Lapeurta, P., Rue, J, Swales, K., & Budge, M. (2002).  
 
The Hopkins Verbal Learning Test and screening for dementia. Dementia and  
 
Geriatric Cognitive Disorders, 13, 13-20. 
 
Hox, J. (2002). Multilevel analysis: Techniques and applications. Mahaw, NJ: Erlbaum.  
 
Jagust, W., Harvey, D., Mangas, D., & Haan, M. (2005). Central obesity and the aging  
brain. Archives of Neurology, 62, 1545-1548. 
Jeong, S., Nam, H., Son, M., Son, E., Cho, K. (2005). Interactive effect of obesity  
indexes on cognition. Dementia and Geriatric Cognitive Disorders, 19, 91-96. 
Kales, A., Caldwell, A.B., Cadieux, R.J., Vela-Bueno, A., Ruch, L.G., & Mayes, S.D.  
 108 
(1985). Severe obstructive sleep apnea II: Associated psychopathology and 
psychosocial consequences. Journal of Chronic Disease, 38, 427-434.  
Katzel, L.I., Busby-Whitehead, M.J., & Goldberg, A.P. (1993). Adverse effects of  
 
 abdominal obesity on lipoprotein lipids in healthy older men. Experimental  
 
 Gerontology, 28, 411- 420. 
 
Kang, Y.W., Na, D.L., & Hahn, S.H. (1997). A validity study on the Korean Mini-Mental  
State Examination (K-MMSE) in dementia patients. Journal of the Korean 
Neurological Association, 15, 300-308.  
Kivipelto, M., Ngandu, T., Fratiglioni, L., Viitanen, M., Kareholt, I., Winblad, B. (2005).  
Obesity and vascular risk factors at midline and the risk of dementia and 
Alzheimer disease. Archives of Neurology, 62, 1556-1560.  
Klonoff, H., Fleetham, J., Taylor, R., & Clark, C. (1987). Treatment outcome of  
obstructive sleep apnea: Physiological and neuropsychological concomitants. 
Journal of Nervous and Mental Disease, 175, 208-212.  
Kopelman, P.G. (2000). Obesity as a medical problem. Nature, 404, 635-643.  
Kortte, C.B., Horner, M.D., & Windham, W.K. (2002). The Trail Making Test, Bart B:  
Cognitive flexibility or ability to maintain set? Applied Neuropsychology, 9, 106-
109. 
Knight, H., Millman, R.P., Gur, R.C., Saykin, A.J., Dohertry, J.U., & Pack, A.I. (1987).  
Clinical significance of sleep apnea in the elderly. American Revision of 
Respiratory Disorders, 136, 845-850.  
Lacritz, L.H., Cullum, M.C., & Weiner. (2001). Comparison of the Hopkins Verbal  
 
Learning Test-Revised to the California Verbal Learning Test in Alzheimer’s  
 109 
 
disease.  Applied Neuropsychology, 8, 180-184.  
 
Lanfranchi, P., & Somers, V.K. (2001). Obstructive sleep apnea and vascular disease.  
Respiratory Research, 2, 315-319.  
Lauer, M.S., Anderson, K.M., Kannel, W.B. & Levy, D. (1991). The impact of obesity on  
left ventricle mass and geometry. Journal of the American Medical Association, 
266, 231-236.  
Lee, M.M., Strauss, M.E., Adams, N., & Redline, S. (1999). Executive functions in  
persons with sleep apnea. Sleep and Breathing, 3, 13-16.  
Levine, A.J., Miller, E.N., Becker, J.T., Selnes, O.A., & Cohen, B.A. (2004). Normative  
data for determining significance of test-retest differences on eight common 
neuropsychological instruments. The Clinical Neuropsychologist, 18, 373-384.  
Malhotra, A., White, D.P. (2002). Obstructive sleep apnoea. Lancet, 360, 237-245. 
Manson, J.E., Willett, W.C., Stampfer, M.J., et al. (1995). Body weight and mortality  
among women. New England Journal of Medicine, 333, 677-685.  
Mokdad, A.H., Marks, J.S., Stroup, D.F., & Gerberding, J.L. (2004). Actual causes of  
death in the United States. Journal of the American Medical Association, 291, 
1238-1245. 
Monasterio, C., Vidal, S., Duran, J., Ferrer, M., Carmona, C., Barbe, F., et al. (2001).  
Effectiveness of continuous positive airway pressure in mild sleep apnea-
hypopnea syndrome. American Journal of Respiratory and Critical Care 
Medicine, 164, 939-943.  
Montplaisir, J., Bédard, M.A., Ficher, F., & Rouleau, I. (1992). Neurobehavioral  
 110 
manifestations in obstructive sleep apnea-hypopnea syndrome before and after 
treatment with continuous positive airway pressure. Sleep, 15, S17-19. 
Munoz, A., Mayoralas, L.R., Barbé, F., Pericas, J., & Agusti, A.G.N. (2000). Long-term  
effects of CPAP on daytime functioning in patients with sleep apnoea syndrome. 
European Respiratory Journal, 15, 676-681.  
Naegele, B., Pepin, J.L., Levy, P., Bonnet, C., Pellat, J., & Feuerstein, C. (1998).  
Cognitive executive dysfunction in patients with obstructive sleep apnea 
syndrome (OSAS) after CPAP treatment. Sleep, 21, 392-397.  
Naegele, B., Thouvard, V., Pepin, J.L., Levy, P., Bonnet, C., Perret, J.E., Pellat, J., &  
Feuerstein, C. (1995). Deficits of cognitive executive functions in patients with 
sleep apnea syndrome. Sleep, 18, 43-52. 
Nelson, H.E. (1976). A modified card sorting test sensitive to frontal lobe defects.  
Cortex, 12, 313-324.  
Nelson, H.E. (1982). Nelson Adult Reading Test Manual. London: The National Hospital  
 
for Nervous Disease.  
 
Nelson, H.E., & O’Connell, A. (1978). Dementia: The estimation of premorbid  
 
intelligence levels using the new adult reading test. Cortex, 14, 234-244.  
 
O’Donnell, J.P., MacGregor, L.A., Dabrowski, J.J., Oestreicher, J.M., & Romero, J.J.  
 
(1994). Construct validity of neuropsychological tests of conceptual and  
 
attentional abilities. Journal of Clinical Psychology, 50, 596-600. 
 
Ohlson, L.O., Larsson, B., Svardsudd, K., Welin, L., Eriksson, H., Willerslmsen, L.,  
 111 
Bjorntorp, P., et al. (1985). The influence of body fat distribution on the incidence 
of diabetes mellitus: 13.5 years of follow up of the participants in the study of 
men born in 1913. Diabetes, 34, 1055-1080.  
Olshansky, J.S., Passaro, D.J., Hershow, R.C., Layden, J., Carnes, B.A., Brody, J., et al.  
(2005).  A potential decline in life expectancy in the United States in the 21st 
century. The New England Journal of Medicine, 352, 1138-1145. 
Pallant, J.F., & Bailey, C.M. (2005). Assessment of the structure of the Hospital Anxiety  
 
and Depression Scale in musculoskeletal patients. Health and Quality of Life  
 
Outcomes, 3, 82-90.  
 
Pi-Sunyer, F.X.  (1993). Medical hazards of obesity. Annals of Internal Medicine, 119,  
655-660.  
Poirier, P., Giles, T., Bray, G., Hong, Y., Stern, J.S., Pi-Sunyer, X., et al. (2006). Obesity  
and cardiovascular disease: Pathophysiology, evaluation, and effect of weight 
loss. Update of the 1997 American Heart Association Scientific Statement on 
obesity and heart disease from the Obesity Committee of the Council on 
Nutrition, Physical Activity, and Metabolism. Circulation, 113, 898-918.  
Raudenbush, S.W., & Byrk, A.S. (2002). Hierarchical linear models: Applications and 
 data analysis methods (2nd ed.). Thousand Oaks, CA: Sage.  
Ravussin, E., Valencia, M.E., Esparza, J., Bennett, P.H., & Schultz, L.O. (1994). Effects  
of a traditional lifestyle on obesity in Pima Indians. Diabetes Care, 17, 1067-
1074.  
Razay, G., Vrugdenhil, A., Wilcock, G. (2006). Obesity, abdominal obesity and  
 112 
Alzheimer disease. (2006). Dementia and Geriatric Cognitive Disorders, 22, 173-
176. 
Redline, S., Strauss, M.E., Adams, N., Winters, M., Roebuck, T., Spry, K., et al. (1997).  
Neuropsycholigcal function in mild sleep-disordered breathing. Sleep, 20, 160-
167.  
Redon, J. (2001). Hypertension in obesity. Nutrition, Metabolism, and Cardiovascular  
Diseases, 11, 344-353.  
Reitan, R.M. (1992). Trail Making Test. Manual for Administration and Scoring. Tuscon,  
AZ: Reitan Neuropsychological Laboratory. 
Rey, A. (1958) L’examen Clinique en Psychologie. Paris: Universitaires de France.  
Royan, J., Tombaugh, T.N., Rees, L., & Francis, M. (2004). The Adjusting-Paced Serial  
Addition Test (Adjusting-PSAT): Thresholds for speed of information processing 
as a function of stimulus modality and problem complexity. Archives of Clinical 
Neuropsychology, 19, 131-143.  
Saint-Cyr, J.A., Taylor, A.E., Lang, A.E. (1988). Procedural learning and neostriatal  
dysfunction in man. Brain, 111, 941-959.  
Salorio, C.F., White, D.A., Picciriool, J., Duntley, S.P., & Uhles, M.L. (2002). Learning,  
memory, and executive control in individuals with obstructive sleep apnea 
syndrome. Journal of Clinical and Experimental Neuropsychology, 24, 93-1000. 
Schachinger, H., Cox, D., Linder, L., Brody, S., & Keller, U. (2003). Cognitive and  
 
psychomotor function in hypoglycemia: Response error patterns and retest  
 
reliability. Pharmacology, Biochemistry and Behavior, 75, 915-920. 
 
Schwartz, M., & Saffran, E. (1987). The American-Nart: Replication and extension of the  
 113 
 
British findings on the persistence of word pronunciation skills in patients with  
 
dementia, unpublished manuscript. Philadelphia.  
 
Shapiro, N.M., Benedict, R.H.B., Schretlen, D., & Brandt, J. (1999). Construct and  
 
concurrent validity of the Hopkins Verbal Learning Test-Revised. The Clinical  
 
Neuropsychologist, 14, 318-334.  
 
Skoog, I., Lernfelt, B., Landahl, S., Palmertz, B., Andreasson, LA., Nilsson, L., et al.  
 
(1996). A 15-year longitudinal study of blood pressure and dementia. Lancet, 347,  
 
11, 1141-1150. 
 
Snujders, T.A.B., & Bosker, R.J. (1999). Multilevel analsis: An introduction to basic and  
 
advanced multilevel modeling. London: Sage.  
 
Steer, R.A., Ball, R., Ranieri, W.F., & Beck, A.T. (1999). Dimensions of the Beck  
 
Depression Inventory-II in clinically depressed outpatients. Journal of Clinical  
 
Psychology, 55, 117-128. 
 
Steinberg, B.A., Bieliaukas, L.A., Smith, G.E., & Ivnik, R.J. (2005). Mayo Older  
Americans Normative Studies: Age-and-IQ-adjusted norms for the Trail Maing 
Test, the Stroop Test, and MAE Controlled Oral Word Association Test. The 
Clinical Neuropsychologist, 19, 329-377. 
Sternberg, S. (1975). Memory scanning: new findings and current controversies.  
 
Quarterly Journal of Experimental Psychology, 27, 1-32.  
 
Stewart, R., Masaki, K., Xue, Q., Peila, R., Petrovitch, H., White, L.R., et al. (2005).  
Archives of Neurology, 62, 55-60. 
Strauss, E., Sherman, E.M.S., & Spreen, O. (2006). A compendium of neuropsychological  
 114 
tests: Administration, norms, and commentary (3rd ed.). New York: Oxford  
University Press.  
Stuss, D.T., Stethem, L.L., Hugenholtz, H., & Richard, M.T. (1989). Traumatic brain  
 
injury: A comparison of three clinical tests and analysis of recovery. The Clinical  
 
Neuropsychologist, 3, 145-156.  
 
Tabachnick, B. G., & Fidell, L.S. (2007). Using Multivariate Statistics (5th ed.). Boston:  
 
 Pearson Education, Inc. 
 
Teunissen, C.E., van Boxtel, M.P.J., Bosma, H., Bosmans, E., Delanghe, J., De Bruijn, C.  
(2003). Inflammation markers in relation to cognition in a healthy aging 
population. Journal of Neuroimmunology, 134, 142-150.  
Thum, Y.M. (1997). Hierarchical linear models for multivariate outcomes. Journal of  
Educational and Behavioral Statistics, 22, 77-108.  
Tiffin, J. (1968). Purdue Pegboard Examiner’s Manual. Rosemont, IL: London House.  
Valencia Flores, M., Bliwise, D.L., Guilleminault, C., Cilveti, R., & Clerk, A. (1996).  
Cognitive function in patients with sleep apnea after acute nocturnal nasal 
continuous positive airway pressure (CPAP) treatment: Sleepiness and hypoxemia 
effects. Journal of Clinical and Experimental Neuropsychology, 18, 197-210.  
Veasey, S.C., Guilleminault, C., Strohl, K.P., Sanders, M.H., Ballard, R.D., Magalang,  
U.J. (2006). Medical therapy for obstructive sleep apnea: A review by the medical 
therapy for obstructive sleep apnea task force of the standards of practice 
committee of the American Academy of Sleep Medicine. Sleep, 29, 1036-1044. 
Wadden, T.A., Brownell, K.D., Foster, G.D. (2002). Obesity: Responding to the global  
epidemic. Journal of Consulting and Clinical Psychology, 70, 510-525.  
 115 
Waldstein, S.R., Katzel, L.I. (2006). Interactive relations of central versus total obesity  
and blood pressure to cognitive function. International Journal of Obesity, 30, 
201-207. 
Ward. M.A., Carlsson, C.M., Trivedi, M.A., Sager, M.A., & Johnson, S.C. (2005). The  
effect of body mass index on global brain volume in middle-aged adults: A cross 
sectional study. BMC Neurology, 5, 1471-2377.  
Wechsler, D. (1955). Manual for the Wechsler Adult Intelligence Scale. San Antonio,  
TX: The Psychological Corporation.  
Wechsler, D. (1981). Manual for the Wechsler Adult Intelligence Scale. The  
Psychological Corporation: New York. 
Wechsler, D. (1944). The Measurement of Adult Intelligence. (3rd ed). Baltimore, MD:  
Williams & Wilkins.  
Wechsler, D., & Stone, C. (1945). Wechsler Memory Scale Manual. New York: The  
Psychological Corporation.  
Wechsler, D. (1997). WMS-III Administration and Scoring Manual. San Antonio, Texas:  
The Psychological Corporation.  
Wilson, C.J., Finch, C.E., & Harvey, J.C. (2002). Cytokines and cognition – The case for  
a head-to-toe inflammatory paradigm. Journal of the American Geriatrics Society, 
20, 2041-2056.  
Wingenfeld, S.A., Holdwick, D.J., Davis, J.L., & Hunter, B.B. (1999). Normative data on  
 
computerized Paced Auditory Serial Addition Task performance. The Clinical   
 
Neuropsychologist, 13, 268-273. 
 
World Health Organization. (1998). Obesity: Preventing and managing the global  
 116 
epidemic. Geneva, Switzerland: Author.   
Young, T., Dempsey, J., Skatrud, J., Weber, S., & Badr, S. (1993). The occurrence or  
sleep-disordered breathing among middle-aged adults. New England Journal of 
Medicine, 328, 1230-1235.  
Zhang, Y., Proenca, R., Maffei, M., Barone, M., Leopold, L., Friedman, J. (1994).  
Positional cloning of the mouse obese gene and its human  
homologue. Nature, 372, 425-432.  
Zigmond, A.S., & Snaith, R.P. (1983). The hospital anxiety and depression scale. Acta  
 
Psychiatrica Scandinavica, 67, 361-370.  
 
Zozula, R., & Rosen, R. Compliance with continuous positive airway pressure therapy:  
Assessing and improving treatment outcomes. Current Opinion in Pulmonary 
Medicine, 7, 391-398 
 
 
 
 
 
